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Poor aqueous solubility is a major impediment to the oral delivery of over 75% of 
pharmaceutical compounds currently under development. The bioavailability of these 
compounds can be enhanced with the use of supersaturating dosage forms, due to their 
high flux rates across the gastrointestinal tract membrane. However, the success of this 
strategy hinges on the ability to inhibit crystallization of the supersaturated drug 
solutions. Polymers can be used to inhibit crystallization and prolong supersaturation, 
however the mechanisms of polymer inhibition are not yet fully understood. Therefore it 
is desirable to understand the attributes that render a polymer effective. In this work, the 
crystal growth rate of a poorly soluble pharmaceutical compound, felodipine, was 
measured in the presence of various polymers. The growth rate studies were performed 
using a rotating disk apparatus so that the growth kinetics could be controlled and 
mathematically modeled. It was found that both polymer ionization state and polymer 
hydrophobicity greatly impacted polymer effectiveness. Investigation of these systems 
with atomic force microscopy (AFM) revealed that these properties significantly 




chain conformation were able to achieve a higher degree of surface coverage than those 
that adsorbed in a coiled globule formation. The surface coverage was found to directly 
correlate to polymer effectiveness. By modeling this correlation using the Kubota-Mullin 
model, polymer effectiveness could be predicted when surface coverage was known. This 
research also assessed the ability of a polymer to impact crystal morphology. It was 
found that when polymers were present during crystal evolution from an amorphous melt, 
they were able to impact the size and shape of the resulting crystals. This in turn 





CHAPTER 1. LITERATURE REVIEW 
1.1 Introduction 
Many factors determine the rate and extent of absorption of an active 
pharmaceutical ingredient (API) from the gastrointestinal (GI) tract.1,2 Fundamentally, 
the API must be able to permeate through the GI tract membrane, and possess adequate 
aqueous solubility.3 Thus, a poorly soluble drug will have limited bioavailability, posing 
a challenge for oral dosage formulations. Modification of the solid state, for example, 
formulation as an amorphous solid, can increase solubility4–6 without compromising 
permeability.7 
The amorphous form possesses higher free energy and enthalpy compared to the 
crystalline form, and has no long-range molecular order.8–10 Thus, the energy required to 
dissolve an amorphous solid is significantly decreased relative to the crystalline form. 
Upon dissolving, the amorphous solid can generate a supersaturated solution.11 The 
supersaturated solution of a drug has a greater thermodynamic activity than its saturated 
solution, which can increase absorption.12–14 However, supersaturated solutions will 
quickly crystallize due to the increased activity; therefore, methods to slow crystallization 
and prolong supersaturation are of great interest. One such method is the use of additives, 
such as polymers, which can effectively inhibit crystal growth and stabilize 




 The overall objective of the work presented in this dissertation was to provide 
valuable insight into the specific mechanisms by which polymers can inhibit crystal 
growth in solution. Recent studies on polymer inhibition, which will be reviewed in the 
following sections, showed that polymer effectiveness varied greatly for a given API. 
Certain polymer properties that impacted effectiveness were identified, however, the 
details of how these properties contributed to effectiveness were unclear. The work 
presented in this dissertation reveals that polymer conformation and consequently, 
surface coverage, are key determinants of polymer effectiveness. 
 
1.2 Broader Impact 
Many industries, including fine chemicals, microelectronics, food, and 
pharmaceuticals, require the ability to control crystallization processes.18 This is because 
crystal form dictates the physical and chemical properties of a compound. In the 
pharmaceutical field, manipulating crystal form can be used as a means to enhance the 
bioavailability of oral dosage forms. This is important because it is estimated that about 
75% - 90% of promising drug candidates have poor aqueous solubility6,19 This 
compromises their absorption due to their inability to dissolve in the aqueous 
gastrointestinal lumen5. Therefore, methods to enhance the solubility, such as utilizing 
the amorphous form of the API, are necessary in order to ensure that pharmaceutical 
companies can put promising drug candidates on the market. 
 Two recently approved therapies highlight the importance of solid form 
manipulation. Vemurafenib is able to treat tumors by inhibiting mutations of the protein 




modest drug exposure, so there was little tumor regression. But higher drug exposure was 
achieved by reformulating vemurafenib as micro-precipitated bulk powder (MBP). Thus, 
by utilizing the amorphous form, the bioavailability was proven to increase tenfold 
causing tumors to shrink significantly.20  
Another example is telaprevir, a treatment for the hepatitis C virus. In its 
crystalline form, telaprevir exhibited a lower aqueous solubility than that of marble. 
However, formulating this API as an amorphous spray dried suspension with a stabilizing 
polymer and surfactant greatly improved its bioavailability, such that the sustained viral 
response (SVR) rates in patients treated with the new telaprevir formulation was 60-
70%.21  
Both of the therapies mentioned above are used to treat serious, life-threatening 
diseases. The ability to improve the bioavailability of these drugs and others that suffer 
from low solubility, has significant implications for patients seeking life-saving 
treatments.    
 
1.3 The Amorphous Form 
Solubility can be expressed as19,22  
 ln! = − ∆!! !!!!!" − ln!    (1.1) 
 
where X is the mole fraction aqueous solubility, ΔSm is the entropy of melting, Tm is the 




coefficient. This expression assumes that heat capacity is independent of temperature. 
The second term in the equation reflects the affinity of the solute for the solvent, or the 
lyophilicity, which can either hinder or aid solubility.  
The first term in equation (1.1) reflects the crystallinity of the solid.22 In 
crystalline solids, molecules are arranged in a tightly packed lattice formation (Figure 
1.1a), maximizing a molecule’s interactions with neighboring molecules, and increasing 
overall stability of the solid. Amorphous solids on the other hand lack long-range 
molecular order (Figure 1.1b), and are considered a supercooled liquid or a glass.8 Thus 
an amorphous solid does not exhibit a phase transition to the liquid state and the first term 
in equation (1.1) can be neglected thereby increasing the mole fraction solubility. 
 
 
Figure 1.1. Molecular arrangements of (a) a crystalline solid, and (b) an amorphous solid 
 
In other words, for a solid to enter into solution, the interactions between 
molecules must be disrupted. Due to the lack of long-range order in an amorphous solid, 
less energy is required (i.e. it is more favorable) to disrupt the intramolecular bonds. 
Upon dissolving, the amorphous solid can generate a supersaturated solution,11 which has 




flux rates, and therefore, higher absorption.12–14 However, supersaturated solutions will 
crystallize rapidly due to the increased thermodynamic driving force, threatening the 
efficacy of this formulation strategy.23 Therefore, it is necessary to stabilize the 
supersaturated solution by inhibiting crystal growth for a sufficient amount of time, such 
that the solute can permeate the GI tract membrane and be absorbed successfully. 
 
1.4 Crystal Growth Theory 
The thermodynamic driving force for crystal growth, σ, is the chemical potential 
difference between a supersaturated and saturated solution of a given substance, Δµ.24 
This can be expressed in dimensionless form in terms of solute activity:25,26 
 σ = !"!" = ln !!!∗     (1.2) 
 
where ab is the solute activity in the bulk solution, a* is the equilibrium solute activity, R 
is the gas constant, and T is the temperature. Equivalently, the driving force can be 
expressed in terms of the activity coefficient, ϒ, and concentration, C:24,26  
 ln !!!∗ = ln !!!!!∗!∗     (1.3) 
 
Activities and activity coefficients are difficult to obtain. Therefore, the driving force is 
often expressed in terms of only the concentration ratio (eq 1.4a and 1.4b) or the 




σ ≈ ln !!!∗      (1.4a) !! ≈ !!!∗ = S     (1.4b) σ! ≈ !! − !∗     (1.4c) 
 
where S is the supersaturation ratio. Such expressions for the driving force in terms of 
concentration assume that ϒb ≈ ϒ* which is valid for ideal solutions with low 
supersaturation (S<1).27 
The overall crystal growth rate, RG, which is the rate of mass deposition, m, onto 
the crystal over time, t, is expressed in terms of the driving force as24 
 R! = !!Aσ! = !"!"     (1.5) 
  
where kG is the growth rate coefficient, A is the crystal surface area, and g is the overall 
growth order.  
Crystallization occurs by two distinct phenomena: nucleation and growth. Nuclei 
must be present in order for growth to occur. Nucleation is the materialization of a new 
solid phase from the supersaturated phase.26 Nuclei can form by the union of solute 
molecules in an uncontaminated homogeneous solution (primary homogeneous 
nucleation). It can be instigated by an impurity that provides an existing surface for solute 
molecules to attach to (primary heterogeneous nucleation). Or it can be induced by seeds 





Once the nucleus reaches a critical size in solution, growth can begin. There are 
many mechanisms for crystal growth described in the literature. Adsorption layer theories 
are widely accepted and they are based on the adsorption of solute molecules onto the 
crystal face starting from a two-dimensional nucleus of critical radius, ρc. The critical 
radius will depend on several properties of the compound as well as the environment:15   
 !! = !"!!!(!"#)     (1.6) 
 
Here, γ is the edge free energy of the compound, a is the area that a growth unit occupies 
on a crystal, kB is the Boltzmann constant, and T is the solution temperature. 
 In the step-growth theory developed by Kossel,28 growth units will attach at the 
highest energy ‘kink’ sites, and continue in a linear step-wise fashion across the width of 
the face, creating steps that are monoatomic in height. In the birth and spread mechanism, 
nuclei form at the edges or on faces of the crystals and monolayer growth proceeds in all 
directions from these nuclei.24,29 Knowledge of adsorption layer theories provides a basis 
for understanding additive inhibition theory (Section 1.5). The work shown in Chapter 6 
of this dissertation provides evidence of these growth mechanisms for the systems studied. 
 
Figure 1.2. Illustrations of the (a) step-growth mechanism, where the arrow is highlighting a kink 




The rate of crystal growth can be expressed by combining equations (1.4c) and 
(1.5): 
 R! = !!A !! − !∗ !    (1.7) 
 
Equation (1.7) is the overall growth rate expression, however, crystal growth involves 
two separate steps, which are considered to occur in series. First, solute diffuses to the 
solid-liquid interface (Figure 1.2a), then it integrates into the crystal lattice. Figure 1.2b 
illustrates the integration process. According to the Gibbs-Volmer theory, once the solute 
arrives at the interface, it can diffuse over the surface until it finds a site to link into the 
lattice.24  
 
Figure 1.3. Illustrations of the two steps of a crystal growth process: (a) mass transfer of solute to 
the interface and (b) integration of solute into the crystal lattice 
 
Each growth step has a different rate associated with it and a different driving 
force. Equation (1.7) can then be separated into two steps:24,26 




Equation (1.8) represents the rate of mass transfer, where kd is the mass transfer rate 
coefficient, and CI is the concentration at the solid-liquid interface. Equation (1.9) 
represents the rate of integration, where kr is the integration rate coefficient, and r is the 
integration rate order.  
 When the rate of mass transfer is slower (i.e. the mass transfer step offers more 
resistance), the growth process is considered to be ‘mass transfer controlled.’ When the 
integration step offers more resistance, the growth process is ‘integration controlled.’ In 
the case of integration-controlled growth, the concentration at the interface, CI will 
approach the bulk concentration, Cb, and equation (1.9) can be approximated as 
 R! = !!A !! − !∗ !    (1.10) 
The Damköhler number (Da) is used to compare the relative contribution of each 
step: 
 Da = !! !!!!∗ !!!!!     (1.11) 
Thus, when Da is large, growth is mass transfer controlled (kd << kr) and when Da is 
small, growth is integration controlled (kr << kd).26 The objective of the work presented in 
Chapter 3 was to separate the roles of mass transfer and integration so that integration-





1.5 Additive Inhibition: Theory and Model 
Supersaturated solutions will crystallize over time, compromising absorption. Thus, 
methods to slow crystallization and prolong supersaturation are of great interest. 
Additives, such as polymers, can effectively inhibit crystal growth and stabilize 
supersaturated solutions by competing for growth unit adsorption sites.15–17 To effectively 
inhibit growth, the impurities do not need to cover the entire crystal surface, rather they 
merely need to disturb the flow of growth layers.24 Cabrera and Vermilyea first proposed 
the pinning mechanism (Figure 1.4) which was then modified by Kubota and Mullin.  
 
Figure 1.4. Depiction of the pinning mechanism due to additive adsorption. 
 
In this mechanism, the impurities adsorb at kink sites along the steps at an 
average distance, l, apart. This forces the steps to curve, thus slowing step advancement. 
The radius of curvature of a pinned step, ρ, is equal to l/2. If ρ ≤ ρc (the critical nucleus 
radius), then step advancement will stop completely. Therefore, Kubota and Mullin have 
expressed the step velocity in the presence of additives, VP, relative to the step velocity of 




Expressing the step velocities in the absence and presence of impurities as a ratio is 
useful because V0/VP is a measure of additive effectiveness. When V0/VP >1, the additive 
is considered effective at slowing crystal growth.  
For many systems, at low supersaturations, additives can slow crystal growth 
significantly, or even stop it completely. However, at high supersaturations, the same 
additive may completely lose its effect.31–33 This impact of supersaturation can be 
explained by equations (1.6) and (1.12). With an increase in S, ρc will decrease, thus 
reducing the effectiveness of the additives.  
Combining equations (1.6) and (1.12), VP/V0 can instead be expressed in terms of 
the useful parameters α, the impurity effectiveness factor, and θ, the impurity fractional 
coverage, 
 
!!!! = 1− !"     (1.13a) ! = !"!!!(!"#)!     (1.13b) ! = !!       (1.13c) 
 
where L is the average distance between active sites available for impurity adsorption.15 
Expressing VP/V0 as equation (1.13a) rather than (1.12) is useful because growth 
inhibition can be then expressed in terms of the impurity fractional coverage, θ, which 
assumes linear adsorption along the steps. This form of the expression is also useful 




in the parameter, L, which will vary for each additive-drug combination. Therefore α 
takes into account the active sites specific to the system under study.30  
The rate of step growth, V, can be difficult to measure experimentally. Thus, 
Kubota and Mullin replaced the relative step velocity VP/V0 by the relative face growth 
rate GP/G0 under the assumption that V is proportional to G. This holds true if the growth 
proceeds by single-layer step growth and if the step heights remain constant.  
It is even easier to experimentally determine overall mass growth rates, RG, than 
individual face growth rates. Garside describes the following relationship between RG 
and face growth rate, G:26 R! = !! G ∙ A!!"    (1.14) 
 
where ζ is the crystal density, A is the total crystal surface area, and Ahkl represents the 
areas of all the individual faces. Therefore equation (1.13a) can be expressed in terms of 
the overall crystal growth rates in the presence (RP) and absence (R0) of impurities as !!!! = 1− !"     (1.15) 
if the following assumptions hold true: the ratio of crystal density to total crystal surface 
area (ζ/A) does not change when impurities are added to the system, and the areas of the 
individual faces (Ahkl) do not change with the addition of impurities. 
 
1.6 Polymer Inhibition of Crystal Growth 
It has become increasingly more common to use polymeric additives as crystal 




energy, ΔG due to favorable polymer-surface interactions. Adsorption causes the polymer 
to lose entropy, which is unfavorable. Therefore, adsorption must be enthalpically driven 
in order for the process to be favorable. In other words, the interaction energy between 
the polymer and drug must be large enough to overcome the entropy loss. Components of 
the interaction energy can include electrostatic, chemical, hydrophobic, and hydrogen 
bonding interactions.34 
The polymer-surface interactions will be influenced not only by the properties of 
the drug and polymer, but also by the liquid medium. If the interactions between the 
polymer and solvent are unfavorable, the polymer will want to minimize its interactions 
with the medium by adsorbing to the solid. If the polymer-solvent interactions are 
favorable, adsorption is less likely, unless the polymer can form even more favorable 
interactions with the drug than with the medium.35 
Recently, there have been increased efforts to determine the factors that impact a 
polymer’s effectiveness as a crystal growth inhibitor. Studies have shown that the 
hydrophobicity match between the polymer and the drug is of fundamental 
importance.36,37 Ilevebare et al. have demonstrated that for moderately hydrophobic drugs, 
the most effective polymers also possessed moderate hydrophobicity. In general for these 
systems, very hydrophobic polymers were ineffective, as were very hydrophilic polymers. 
This result could be explained by the adsorption theory described in the preceding 
paragraph. It is likely that very hydrophilic polymers will interact primarily with the 
solvent and little adsorption will occur. Very hydrophobic polymers, on the other hand, 





decreasing surface coverage.37 The objective of the work presented in Chapter 5 of this 
dissertation was to provide evidence of these phenomena.  
The above findings suggest that hydrophobic forces may be the key driving force 
for polymer adsorption in solution. However it has also been shown that specific surface-
polymer interactions, such as hydrogen bonding, can drive adsorption from solution as 
well.38,39 It is already well known that specific interactions are key for polymer 
effectiveness in amorphous solid dispersions (amorphous drug dispersed in a polymeric 
matrix).40,41 Studies on solid dispersions have demonstrated the importance of the relative 
functional group chemistries of the drug and polymer.42 According to Black and Davey, 
effective polymers in solution should contain a part similar to the drug molecule – the 
part that adsorbs to the crystal – and the part that emerges from the crystal should be 
different enough from the host molecule that its binding energy is modified, contributing 
to less favorable incorporation of growth units.17 
In a recent study by Ilevbare et al., it was observed that the presence of ionizable 
functional groups on a polymer and a higher degree of substitution increased polymer 
effectiveness.37 The authors completed a subsequent study comparing the effectiveness of 
several ionizable polymers at two pH conditions, above and below the pKa of the 
functional groups.33 The polymers were consistently more effective at the higher pH 
where they were ionized, despite having similar extent of adsorption to the crystal.  
It was hypothesized from these findings that pH most likely affected the adsorbed 
polymer conformation.43–45 Ionic polymers, or polyelectrolytes can undergo reversible 
conformation changes with an increase or decrease in pH due to shifts in charge density 




dissertation was to gain more insight into the relationship between polymer conformation 
and crystal growth inhibition. 
Due to the effect polymers can have on the advancement of growth steps, over 
time the polymers can impact crystal morphology. Some studies have found that the 
presence of impurities alter crystal size and shape.36 Holder and Winkler found that 
polymers selectively poisoned the 011 face of n-paraffin wax. The crystals proceeded to 
grow only in the remaining crystallographic planes and the thus the polymers modified 
the crystal habit. Land et al and Gratz and Hillner found in their respective studies that 
impurities distorted the shape of macrosteps, or terraces. The objective of the work 
presented in Chapter 6 of this dissertation was to evaluate the impact of changes in 
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CHAPTER 2.  METHODS AND MATERIALS 
2.1 Rotating Disk Apparatus Theory  
Crystal growth rates are impacted by the rate of solute mass transfer to the crystal 
interface, and rate of integration into the lattice, as explained in Chapter 1. A rotating disk 
apparatus (RDA) can be utilized to separate the roles of mass transfer and integration 
because it induces controlled forced convection. The rotation of the disk draws the fluid 
up in the axial direction toward the surface then throws it outward in the radial and 
tangential directions across the disk surface1 (see Figure 2.1). Thus, the rate of the mass 
transfer step will depend on the angular velocity, ω, of the rotating disk.  
 




The Navier-Stokes and continuity equations for the fluid motion due to a rotating 
disk have been solved,2–5 and the axial velocity component, vy, was determined to be:1 
 
v! ≈ −0.51 !!! !!    for ! ≪ !!  (2.1) 
 
where v is the kinematic viscosity of the solution. Since forced convection toward the 
disk is in the axial (y) direction only, the concentration will not be a function of the radial 
or tangential directions. Thus, the Navier-Stokes convective diffusion equation (in 
cylindrical coordinates) becomes: v! !"!" = D !!!!!!     (2.2a) 
with the boundary conditions ! = 0, C = 0     (2.2b) ! → ∞, C = Cb    (2.2c) 
where D is the diffusion coefficient of the solute in the solution. Solving for the 
concentration, C, and combining with equation (2.1), then differentiating to obtain mass 
flux, j, to the disk surface, the result is:1 ! = D !"!" = 0.6205D!/!!!!/!!!/!Cb (2.3) 
Thus, the mass transfer rate coefficient, kd depends on ω according to the following 




Therefore, when the crystal growth rate is mass transfer-controlled, it will depend on the 
rotational speed of the disk, ω, according to equation (2.4). As ω continues to increase, it 
will reach a critical velocity, ωc, where the growth rate plateaus because it is no longer 
dependent on disk rotational speed. Above ωc the growth rate is now limited by how 
quickly solute can integrate into the crystal lattice. Thus, the correlation between crystal 
growth rate, RG and ω1/2 should follow the trend shown in Figure 2.2. 
 
 
Figure 2.2. Theoretical correlation between growth rate and RDA rotational speed, showing mass 
transfer-controlled growth (I) and integration-controlled growth (II). ωc denotes the critical disk 
rotational speed above which the growth rate is independent of the rotational speed. 
 
 
In order for equation (2.4) to accurately describe the mass transfer, several criteria 
must be met:8 
i) Flow over the disc must be laminar.  
ii) Edge effects must be negligible. 
iii) The disc must be planar. 
iv) The disc surface must be ‘smooth’.  




Explanations for how these criteria are met will be given in Chapter 3. In that chapter, a 
rotating disk apparatus was utilized to isolate the rate of integration and extract kinetic 
growth parameters. Once the integration-controlled growth regime was determined, the 
growth rate experiments in the following chapters were performed at rotational speeds 
above ωc. This is because the integration rate is the step that is impacted by polymer 
adsorption. 
 
2.2 Atomic Force Microscopy 
Atomic Force Microscopy (AFM) is a widely-used scanning probe microscopy. 
This method can perform force measurements as well as topographical imaging. In this 
study, the mode of interest is imaging. The sample is placed on a piezoelectric column 
which can move in the x-, y-, and z-directions. A flexible cantilever tip placed above the 
sample interacts with the surface. A laser reflects off the cantilever to a photodetector. 
Therefore, as the cantilever moves due to attractive or repulsive forces from the surface, 
the deflections are recorded.9 The deflections are combined with the x-, y-, and z-
positions on the surface to create a topographical map. Analysis of topographical images 






Figure 2.3: Schematic of an atomic force microscope 
 
For this study, the AFM was run in tapping mode, during which the cantilever 
oscillates at a resonant frequency. The phase response of the oscillating cantilever is of 
particular interest. During imaging, the phase lag between the excitation force and 
cantilever oscillation is recorded to produce a phase-contrast image. This phase lag is 
very useful to reveal differences in material properties. Thus, it is good for differentiating 
between surface components, revealing variations that the height measurements may not 
detect.10 This is particularly useful for detecting polymers because the viscoelasticity will 
differ from that of the drug surface. 
AFM coupled with infrared spectroscopy (AFM-IR) was also used in this work. 
The sample was illuminated from below with a laser, causing the sample to expand and 
contract. The amount of expansion and contraction correlated to how much IR 
illumination the sample absorbed at the particular wavelength. The AFM cantilever probe 
would oscillate due to the expansion and the amplitude of oscillation was recorded. This 





Figure 2.4. Schematic of AFM coupled with infrared spectroscopy 
 
2.3 Materials 
 The active pharmaceutical ingredient utilized as a model compound in this study 
was felodipine, a calcium channel blocker which treats hypertension. Felodipine has a 
low equilibrium solubility (C* = 0.5µg/ml at 25°C.11) and its crystal growth and 
nucleation kinetics have been well-studied.11–13 The polymers used in this study were 
hydroxypropylmethyl cellulose acetate succinate (HPMCAS) grade LF, 
hydroxypropylmethyl cellulose (HPMC), polyvinylpyrrolidone (PVP), poly(acrylic acid) 
(PAA), poly(vinyl acetate) (PVAc) poly(vinylpyrrolidone vinyl acetate) (PVPVA), and 
poly(2-vinylpyridine) (P2VP). The chemical structures of felodipine and these polymers 





Figure 2.5. Chemical structures of (a) felodipine, (b) PAA, (c) P2VP, (d) PVP, (e) PVAc,  
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CHAPTER 3.  UNDERSTANDING CRYSTAL GROWTH KINETICS IN THE 
ABSENCE AND PRESENCE OF A POLYMER USING A ROTATING DISK 
APPARATUS 
This chapter is a preprint with minor modifications of a manuscript submitted to Crystal 
Growth and Design with the same title by: Caitlin J. Schram, Ryan J. Smyth, Lynne S. 
Taylor, and Stephen P. Beaudoin 
 
3.1 Abstract 
Polymer inhibition of crystal growth from supersaturated solutions is an important 
area of study, particularly in the pharmaceutical field. Polymers can be used to modify 
crystal morphology or to slow crystal growth with the goal of enhancing oral drug 
absorption. In order to fully understand the effect of polymers on crystal growth it is 
important to understand the kinetics of the integration step. In this study, a rotating disk 
apparatus is used to isolate the integration step from the diffusion step so that the 
integration kinetics can be determined for growth rates in the absence and presence of 
polymers. The results indicate that the presence of polymers in solution greatly impacts 
the integration step, and has no impact on the mass transfer kinetics.
 29 
3.2 Introduction 
Solution crystallization is a phenomenon central to many industries and fields of 
research. It is highly desirable to be able to manipulate a crystallization process because it 
can have a large impact on the physicochemical properties, and therefore the quality, of 
the product.1 Modification of crystal growth can be achieved through changes in the 
process environment, such as temperature or solvent. Another increasingly common 
approach to manipulate crystal form is to use polymeric additives.2,3  
 In the pharmaceutical field, polymers can be used to slow crystal growth rates and 
maintain supersaturated solutions in vivo, which will ultimately enhance drug delivery.4,5 
The use of this approach is of special interest for drugs that exhibit poor aqueous 
solubility, and thus are formulated as amorphous solids.6–8 In order to effectively inhibit 
crystal growth, it is important to have a good understanding of the kinetics of 
crystallization as well as a mechanistic understanding of how polymers inhibit growth.  
 Crystal growth occurs by two phenomena in series: transport of solute to the 
crystal-liquid interface, and integration of solute into the lattice.9,10 It is likely that 
polymers inhibit growth by inhibiting the integration step, because they compete with 
growth units for active sites on the surface.11–13 Once adsorbed to a site, they create a 
mechanical barrier for further growth units to attach at that site.13 It is therefore important 
to isolate the integration step to better study polymer inhibition. This can be done using a 
rotating disk apparatus.10 Rotating disks have traditionally been used to study the kinetics 
of chemical or electrochemical reactions.14,15 Relatively few studies have used rotating 
disks to study crystal growth,16,17 and currently this technique has not been used to study 
polymer inhibition of crystal growth.   
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 The objective of this work was to measure crystal growth rates of a poorly water-
soluble drug in the absence and presence of a polymer using a rotating disk apparatus. 
This will provide insight into the kinetics of crystal growth when polymers are present in 
the system, therefore providing a better mechanistic understanding of how polymers 
inhibit crystal growth.  
 
3.3 Experimental Section 
3.3.1 Materials 
Felodipine was provided by Attix (Toronto, Ontario, Canada). Methanol (HPLC 
grade) was purchased from Avantor Performance Materials (Center Valley, PA). 
Hydroxypropylmethyl cellulose acetate succinate (HPMCAS) LF grade, Mw 18 000 g 
mol-1, was supplied in powder form by Shin-Etsu Chemical Co, Ltd. (Tokyo, Japan). 50 
mM pH 6.8 phosphate buffer was used as the crystallization medium in all growth 
experiments. HPMCAS was pre-dissolved in the buffer for experiments where crystal 
growth rates were measured in the presence of polymer. The molecular structures of 
felodipine and HPMCAS are given in Figure 2.5. 
 
3.3.2 Rotating Disk Apparatus 
The experimental apparatus is illustrated in Figure 3.1a. The rotating disk 
apparatus (RDA) was provided by Princeton Applied Research (Oak Ridge, TN. Model 
#616). Seed crystals were mounted on a disk in a custom-made holder at the bottom of 
the RDA shaft, which rotated with angular velocity, ω. The disk was submerged in buffer 
solution (60 mL) containing dissolved felodipine alone, or containing both dissolved 
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felodipine and dissolved HPMCAS. The solution was contained in a jacketed beaker 
connected to a circulating water bath held at a constant temperature, 25°C. A UV probe, 
which was used to measure the amount of dissolved felodipine in solution (see section 
3.3.3), was also submerged in the solution.  
 
Figure 3.1. (a) Schematic of the experimental system, showing the seed crystal holder (I), 
rotating shaft (II), jacketed vessel (III), and UV probe (IV); and (b) close-up image of custom-
made seed crystal holder. Liquid flow patterns induced by the rotating disk are also shown. 
 
 Figure 3.1b shows an image of the custom-made Teflon seed crystal holder that 
was mounted at the bottom of the rotating shaft. Felodipine crystals, as supplied by the 
manufacturer were melted and poured into the custom holder. The surface of the melt 
was flattened using a glass coverslip and the melt was allowed to solidify. The surface 
must be completely flat and flush with the rim of the holder in order to fulfill criterion (iii) 
below, and therefore be suitable for use in the rotating disk apparatus. The amorphous 
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felodipine surface was then re-crystallized by exposure to an atmosphere of 75% relative 
humidity. 
 Several criteria must be met in the execution of experiments in order mass 
transfer to be accurately described by equation (2.4): 
i) Flow over the disk must be laminar.18  
 
This criterion is met if Re!"#$ = !!!!!  < 2x105. The radius, rd, of the disk used 
in this study was 3 mm, and the highest rotational speed used was ω = 733 
rad/s. (The value of ν is given in Table 3.1). Thus the maximum Redisk = 
7.2x103 which is < 2x105, therefore all experiments were run well within the 
laminar region. Additionally, Redisk should remain above 1x102 to avoid 
effects of natural convection. This condition was also satisfied since the 
minimum value of Redisk at the lowest rotational speed used, ω = 20.9 rad/s, is 
2.1x102. 
ii) Edge effects must be negligible.18,19 
 
To meet this criterion, the radius of the disk, rd, must be > δH, where δH is the 
hydrodynamic boundary layer, which can be expressed as δ! = 3.6 !! !.!. 
The lowest rotational speed used in this study was ω = 20.9 rad/s, which 
yields δH = 0.75 mm. Thus r = 3 mm > δH for all experiments. 
iii) The disk must be planar.10 
 
This criterion was satisfied due to the methods employed for seed crystal 
preparation as explained above.  
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iv) The disk surface must be ‘smooth.’10 
 
This criterion is met if the average height of the roughness elements of the 
crystal surface, Rq,av < δH. Characterization with atomic force microscopy of 
seed crystals revealed R q,av = 32.6 nm. The hydrodynamic boundary layer will 
be at a minimum at the highest rotational speed, ω = 733rad/s. At this speed, 
δH = 0.11 mm which is greater than Rq,av. Thus, this criterion was satisfied. 
v) The fluid must be considered an infinite expanse.19 
 
This criterion is met if the distance from the disk surface to the reservoir walls, 
and the distance from the disk to the air-solution interface are both >> δH. δH 
will be at a maximum at the lowest rotational speed, ω = 20.9 rad/s, which 
yields δH = 0.75 mm. Thus, this criterion was met by ensuring that the 
distance from the disk to the walls and from the disk to the solution interface 
were at least 7.5 mm. 
 
3.3.3 Crystal Growth Rate Measurements 
The growth rate of felodipine was measured in the absence and presence of 
HPMCAS. A stock solution of 10 mg/mL solubilized felodipine was prepared by 
dissolving felodipine in methanol. Supersaturated aqueous solutions were then generated 
by adding a small amount of the felodipine stock solution to pH 6.8 buffer alone, or 
buffer containing pre-dissolved HPMCAS (5 µg/mL). The equilibrium concentration, C*, 
of felodipine is approximately 0.5 µg/mL at 25°C.20 The experiments performed to 
determine the effect of rotational speed on the growth rate were carried out at initial bulk 
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concentration, Cb = 2 µg/mL. Experiments performed to determine the integration rate 
constant, kr, and growth order, r, were carried out at Cb = 1 µg/mL, 1.5 µg/mL, 2 µg/mL, 
2.5 µg/mL, and 3 µg/mL. 
The concentration of felodipine in solution as a function of time was measured to 
determine a desupersaturation profile. This profile is considered to be directly 
proportional to the growth rate of felodipine, RG. Immediately after generation of 
supersaturated solutions, desupersaturation profiles were measured using a CCD Array 
UV-vis Spectrometer (SI Photonics, Tuscon, AZ). The intensity of an absorbance peak of 
felodipine (wavelength 238 nm) was recorded at 10-second intervals for 1 hour. 
Calibration solutions, prepared in methanol, were used to correlate peak intensity to 
concentration. The slope of the resulting concentration v. time curve was recorded as the 
growth rate, RG. All experiments were performed in triplicate. 
 
3.4 Results and Discussion 
The growth rate of felodipine was measured at various rotational speeds using a 
rotating disk apparatus. A plot of felodipine growth rate as a function of rotational speed, 
ω1/2, is shown in Figure 3.2. The results show that at first the growth rate increases 
linearly with increasing rotational speed. Eventually, the growth rate plateaus, remaining 
at a constant value, independent of ω.  
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Figure 3.2. Plot of felodipine crystal growth rate (initial Cb = 2 µg/mL) as a function of RDA 
rotational speed. Experimental growth rates (blue !) were measured in triplicate and error bars 
indicate one standard deviation from the mean. The theoretical curve (dashed line) was generated 
from equations (3.1) and (1.10). 
 
The observed experimental trend is in agreement with rotating disk apparatus 
theory (Figure 2.2). At lower rotational speeds, the crystal growth rate is limited by the 
rate of mass transfer of solute to the solid-liquid interface. Thus, as the rotational speed 
increases, so does the forced convection rate, which increases the overall crystal growth 
rate. At higher rotational speeds, the crystal growth rate is limited by the rate of 
integration of growth units into the crystal lattice. This rate is independent of bulk fluid 
velocity, thus the rate remains constant as rotational speed increases. 
For mass transfer-controlled growth, the growth rate can be expressed by equation 
(1.8), wherein the rate coefficient, kd, depends on ω1/2 according to equation (2.4). 
Combining equations (1.8) and (2.4) results in the following expression which relates the 
overall growth rate, RG to the rotational speed, ω1/2: 
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R! = 0.6205!!/!!!!/!!!/!A !! − !!  (3.1) 
 
Equation (3.1) was used to model the experimentally determined growth rates of 
felodipine at rotational speeds below ω1/2 = 17.7 (rad/s)1/2. The diffusion coefficient, D, 
was estimated using the Stokes-Einstein equation: 
 D = !!!!!"!!      (3.2) 
 
where kB is the Boltzmann constant, T is the temperature, η is the dynamic viscosity of 
the medium, and rh is the hydrodynamic radius of a felodipine growth unit in solution. 
The numerical values of the constant parameters used in equations (3.1) and (3.2) are 
given in Table 3.1.  
 
Table 3.1. Values used in equations (3.1) and (3.2) to calculate mass transfer-controlled crystal 
growth rates of felodipine. 
 
Parameter Value 
ν 9.15 x 10-7 m2/s 
A 2.83 x 10-5 m2 
Cb 2 µg/mL 
kB 1.38 x 10-23 J/K 
T 298.15 K 
η 9.10 x 10-4 Pa"s 
rh 3.50 x 10-10 m 
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The value of T and Cb were set experimentally, and Cb is the initial bulk 
concentration of felodipine. A is the nominal cross sectional area of the crystalline 
surface. The values of η and ν were found in the literature for water at 25°C.21 The value 
of rh was estimated using the crystal structure visualization software Mercury,22 wherein 
the ‘measure distances’ tool was used to measure the length of a felodipine molecule.   
 The concentration at the interface, CI is not a constant. It will increase and 
approach the bulk concentration, Cb as the rotational speed increases,10 bringing more 
solute to the interface. Thus, the boundary conditions for CI are: 
 
ω = 0; CI = C*     (3.3a) 
ω # ∞; CI # Cb    (3.3b) 
 
The relationship between CI and ω was determined to be 
 !! = !∗ + 0.024!!/!    (3.4) 
 
Theoretical growth rates were determined for 0 < ω1/2 < 17.7 (rad/s)1/2 by substituting 
equation (3.4) for CI along with the values given in Table 3.1 and the calculated value of 
D into equation (3.1). The theoretical curve is plotted (dotted line) along with the 
experimental values in Figure 3.2.  
 For ω1/2 > 17.7 (rad/s)1/2 the growth rate plateaus at a constant value. Here, the 
growth rate is limited by the rate at which growth units can integrate into the lattice. This 
growth rate can be described by equation (1.10). In order to model the integration-
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controlled growth rate using this equation, the rate coefficient, kr, and the integration 
order, r, must be known. These can be determined experimentally by measuring the 
crystal growth rate at various supersaturation conditions at a rotational speed above 17.7 
(rad/s)1/2 (when growth is integration-controlled). Since the growth rate correlates to (Cb - 
C*) according to equation (1.10), plotting RG/A v. (Cb - C*)  (Figure 3.3) allows for 
extrapolation of the values of kr and r by determining the equation of the best-fit curve. 
(Equation 3.5).  
 
 
Figure 3.3. Plot of integration-controlled growth rate as a function of the concentration gradient 
utilized to extrapolate the values of kr and r. Measurements were performed in triplicate and error 
bars indicate one standard deviation from the mean. 
 
!!! = !! !! − !∗ ! = 5.67x10!! !! − !∗ !.!"  (3.5) 
 
Thus according to equation (1.10), kr is equal to the coefficient in equation (3.5), 
5.7 x 10-5 m/s, and r is equal to the exponent, 1.24. Plugging these values along with the 
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values of A, Cb, and C* into equation (1.10), the theoretical integration-controlled growth 
rate was determined to be RG = 2.56x10-3 µg/s, which agrees quite well with the 
experimentally determined growth rates, as shown by the dotted line in Figure 3.2. 
 The Damköhler number, Da, which represents the ratio of the integration and 
mass transfer rate coefficients (equation 1.11), was plotted as a function of RDA 
rotational speed. The result is shown in Figure 3.4. 
 
 
Figure 3.4. Plot of the Damköhler number as a function of rotational speed showing the transition 
from mass transfer to integration-controlled growth. 
 
In agreement with RDA theory, at low rotational speeds, Da is large, indicating 
mass transfer-controlled growth (kr >> kd). As rotational speed increases, Da becomes 
smaller. This indicates that the growth rate switches over to being controlled by the 
integration step (kd >> kr).  
 The good agreement between the experimentally-measured growth rates of 
felodipine and the theoretically-determined growth rates (from equations 3.1 and 1.10) 
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validate the use of the rotating disk apparatus to extract kinetic information. Thus, using 
this method to measure crystal growth rates in the presence of a polymer should provide 
insight into growth inhibition.   
The growth rate of felodipine was measured at various rotational speeds in the 
presence of the polymer HPMCAS. The results are presented in Figure 3.5 along with the 
pure felodipine growth rate results for comparison.  
The observed and predicted growth rates in the presence of HPMCAS follow the 
same overall trend as those of the pure drug; at first there is a linear increase in growth 
rate with rotational speed until the growth rate reaches a plateau indicating integration 
control. However, the magnitude of the growth rate at all rotational speeds is reduced due 
to the adsorption of HPMCAS on active sites at the solid-liquid interface. The adsorbed 
polymer creates a barrier, preventing felodipine growth units from attaching to the crystal, 
thereby slowing crystal growth.11 Evidence of HPMCAS adsorption to felodipine has 
been confirmed using atomic force microscopy (AFM),23 and these results will be shown 
in Chapters 4 and 5. 
 As will be discussed in more detail in Chapter 5, the fraction of felodipine surface 
covered by adsorbed polymers was measured using AFM for nine different polymer 
systems. It was found that adsorbed polymer surface coverage, Φ, correlated linearly to 
polymer effectiveness, RG/RP, where RP is the growth rate of felodipine in the presence of 
polymers (see Figure 5.5). This correlation was then modeled using the approach 
developed by Kubota and Mullin11,13 (equation 1.15). Briefly, all parameters in the model 
were known or could be determined experimentally (see Table 5.2) except the distance 
between adsorbed polymers, l. Thus, values for l were fitted to determine a general 
 41 
relationship between l and Φ (equation 5.3). Substituting this into the model, it was 
determined that polymer effectiveness, RG/RP, is related to fractional polymer surface 
coverage, Φ, according to the following relationship:24 
 
!!!! = 3.918Φ+ 1    (3.6) 
 
Applying this relationship to the current study, theoretical RP values could be 
calculated from the theoretical RG values determined in this study and the experimentally 
measured HPMCAS fractional surface coverage (see Chapter 5), Φ = 0.53.24 This curve 
is plotted along with the experimental values in Figure 3.5 (red dotted line).  
 
 
Figure 3.5. Plot of felodipine crystal growth rate (initial Cb = 2 µg/mL) as a function of RDA 
rotational speed. Experimental growth rates in the absence (blue !) and presence (red $) of 
HPMCAS were measured in triplicate and error bars indicate one standard deviation from the 
mean. The theoretical curve for pure felodipine growth rates (blue - -) was generated from 
equations (3.1) and (1.10). The theoretical curve for growth in the presence of HPMCAS (red − −) 
was generated from equation (3.6). 
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It can be seen that the theoretical curve agrees with the experimental data 
regardless of whether the growth is mass transfer or integration controlled. This result 
confirms that the reduction in growth rate when polymers are present is purely a surface 
coverage effect even when the growth rate is mass transfer controlled. Thus, from 
equation (1.8), the reduction in growth rate can be attributed to a reduction in the nominal 
surface area available for integration, A, due to polymer adsorption at active growth sites, 
as well as changes in the interface concentration, CI. The rate coefficient, kd, however, 
will remain the same as the pure drug rate coefficient at each rotational speed, ω. This 
implies that polymers do not impact the kinetics of the mass transfer step. 
The integration constants, kr and r, for growth in the presence of HPMCAS were 
determined using the same approach used to determine the pure drug growth constants. 
The resulting values are displayed in Table 3.2 along with the integration constants of 
pure felodipine.  
 
Table 3.2. Integration constants for felodipine crystal growth in the absence and presence of 
HPMCAS 
 
 kr (m/s) r 
Pure felodipine growth 5.7 x 10-5 1.24 
Growth with HPMCAS 1.4 x 10-5 1.75 
 
The rate constant, kr, was reduced for growth in the presence of HPMCAS, and 
the integration order, r was increased. The rate of integration depends on how quickly a 
solute molecule can position itself in the crystal lattice. This rate will decrease due to the 
presence of adsorbed polymers because as growth units diffuse across the surface in 
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search of active sites, the number of available sites will be reduced. This barrier to 
integration created by the adsorption of HPMCAS is reflected in the change to kr.  
The increase in the integration order, r, may be due to a shift in growth 
mechanism when polymers are present. Crystal growth of the pure drug proceeds in a 
linear step-wise fashion as described in Chapter 1 (Section 1.4). When HPMCAS is 
present, the steps are pinned and are forced to curve. Thus the presence of adsorbed 
polymers can result in a shift in growth mechanism, which will likely impact the order of 
integration. 
 Previous studies in which overall crystal growth rates were measured in the 
absence and presence of polymers have shown that the overall growth order (g in 
equation 1.7) increases when polymers are present, indicating a shift toward integration-
controlled growth.20 Studying growth with an RDA and isolating the integration step 
confirms that when polymers are present, the integration step is slowed. Thus, it offers 
more resistance to the overall growth rate resulting in the shift toward integration control. 
 
3.5 Conclusions 
A rotating disk apparatus was used to study the kinetics of crystal growth of 
felodipine in the absence and presence of the polymer, HPMCAS. The use of the RDA 
enabled the isolation of the mass transfer and integration steps so that the kinetic rate 
constants for each step could be determined. In the presence of polymer, it was shown 
that the felodipine crystal growth rate was slowed in both the mass transfer-controlled, 
and integration-controlled regions due to adsorption of the polymer on the crystal surface. 
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The use of this technique in crystal growth inhibition studies can enhance our 
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CHAPTER 4. IMPACT OF POLYMER CONFORMATION ON THE CRYSTAL 
GROWTH INHIBITION OF A POORLY WATER-SOLUBLE DRUG IN 
AQUEOUS SOLUTION 
This chapter is a reprint with minor modifications of a manuscript published in Langmuir 
in December 2014 with the same title by: Caitlin J. Schram, Stephen P. Beaudoin, and 
Lynne S. Taylor. 
 
4.1 Abstract 
Poor aqueous solubility is a major hindrance to oral delivery of many emerging 
drugs.  Supersaturated drug solutions can improve passive absorption across the 
gastrointestinal tract membrane as long as crystallization can be inhibited, enhancing the 
delivery of such poorly soluble therapeutics. Polymers can inhibit crystallization and 
prolong supersaturation, therefore it is desirable to understand the attributes which render 
a polymer effective. In this study, the conformation of a polymer adsorbed to a crystal 
surface, and its impact on crystal growth inhibition was investigated. The crystal growth 
rate of a poorly soluble pharmaceutical compound, felodipine, was measured in the 
presence of hydroxypropyl methylcellulose acetate succinate (HPMCAS) at two different 
pH conditions: pH 3 and pH 6.8. HPMCAS was found to be a less effective growth rate 
inhibitor at pH 3, below its pKa. It was expected that the ionization state of HPMCAS 
would most likely influence its conformation at the solid-liquid interface. Further 
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investigation with atomic force microscopy (AFM) revealed significant differences in the 
conformation of HPMCAS adsorbed to felodipine at the two pH conditions. At pH 3, 
HPMCAS formed coiled globules on the surface, whereas at pH 6.8, HPMCAS adsorbed 
more uniformly. Thus it appeared that the reduced effectiveness of HPMCAS at pH 3 
was directly related to its conformation. The globule formation leaves many felodipine 
growth sites open and available for growth units to attach, rendering the polymer less 
effective as a growth rate inhibitor. 
 





Manipulating crystal formation is of fundamental importance to several fields 
including biomineralization, organic electronics and drug delivery. While the impact of 
polymers on inorganic crystallization1,2 and the effect of low molecular weight additives 
on organic crystallization3,4 have been widely studied, polymeric modification of 
crystallization in aqueous solutions of low molecular weight organic molecules is not 
widely understood.  
There is growing interest in combining polymers with poorly water soluble drugs 
to form amorphous drug-polymer blends, with the goal of enhancing oral 
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bioavailability.5,6 The amorphous system is expected to generate a supersaturated solution 
in vivo upon dissolution.7,8 This is because the amorphous form possesses higher free 
energy and enthalpy compared to the crystalline form, and has no long-range molecular 
order.9–11 Thus, the energy required to dissolve an amorphous solid is significantly 
decreased relative to the crystalline form. Supersaturated solutions lead to higher 
membrane flux rates and hence can significantly improve passive drug absorption.5,6,12–14 
Therefore, amorphous drug-polymer blends can be used to improve the delivery of drugs 
with solubility-limited absorption. This is a pressing issue since it is estimated that up to 
80% of investigational drugs have suboptimum aqueous solubility15. The success of this 
strategy can be highlighted with two examples of recently approved therapies: the 
protease inhibitor telaprevir5 which is used to treat hepatitis C infections, and the B-Raf 
inhibitor, vemurafenib,6 used for melanoma. Both were developed as amorphous 
formulations in order to achieve adequate clinical efficacy, which could not be achieved 
with a crystalline form of the drug.  
The supersaturated solutions generated from amorphous solids will typically 
crystallize very rapidly because of the strong thermodynamic driving force.8 
Consequently, employing additives that slow crystallization is critical when using 
supersaturating dosage forms. Additives can effectively stabilize supersaturated solutions 
by either disrupting nucleation, or inhibiting crystal growth by adsorbing to growth sites 
and acting as a mechanical barrier16–18 Recently, there have been increased efforts to 
determine the factors that impact the effectiveness of polymers as a crystal growth 
inhibitors. Key factors thought to be of importance are the hydrophobicity match between 
the polymer and drug,19,20 and the ability of the polymer to form specific interactions via 
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hydrogen bonds to the drug.21,22 In a recent study, it was observed that pH impacted the 
effectiveness of several ionizable polymers.23 The polymers were consistently more 
effective at higher pH where they were highly ionized, despite having a similar extent of 
adsorption to the crystal at both pH values. A number of studies have shown that pH 
affects polymer conformation.24–26 When a polymer is ionized, the charged functional 
groups will self-repulse, causing the polymer chain to extend. In the unionized state, the 
polymer will coil due to intramolecular hydrogen bonding.26 Roiter and Minko confirmed 
these conformational transitions of poly(2-vinylpyridine) chains in aqueous solution as a 
function of pH using atomic force microscopy (AFM).27 
The objective of this study was to investigate the conformation of polymers on the 
surface of a drug crystal as a function of pH. It is hypothesized that pH influences the 
conformation of the adsorbed polymers at the solid-liquid interface, and that these 
changes in polymer conformation impact their ability to inhibit crystal growth. To test 
this hypothesis, the growth rate of the model compound, felodipine, was measured in the 
absence and presence of the ionic polymer, hydroxypropyl methylcellulose acetate 
succinate (HPMCAS) at different pH conditions. The conformation of HPMCAS 
adsorbed to felodipine at these same pH conditions was characterized using AFM phase 
imaging.  
4.3 Experimental Section 
4.3.1 Materials 
Felodipine was provided by Attix (Toronto, Ontario, Canada). Methanol was 
purchased from Avantor Performance Materials (Center Valley, PA). The carboxylated 
polymer used in this study was hydroxypropylmethyl cellulose acetate succinate 
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(HPMCAS) grade LF, MW 18,000 g mol-1, provided by Shin-Etsu Chemical Co, Ltd. 
(Tokyo, Japan) in powder form. The crystallization and adsorption media used in the 
growth and AFM experiments were 50 mM pH 3 phosphate buffer and 50 mM pH 6.8 
phosphate buffer. The chemical structures of felodipine and HPMCAS are shown in 
Figure 2.5. 
 
4.3.2 Crystal Growth Rate Measurements 
The effectiveness of HPMCAS as a crystal growth inhibitor was investigated at 
pH 3 and pH 6.8 by measuring the growth rate of felodipine in the absence and presence 
of HPMCAS. The pH values of 3 and 6.8 were chosen for this study because HPMCAS 
grade LF has a pKa of 5.5. Thus HPMCAS will be in different ionization states at the two 
experimental pH values. The concentration of felodipine in solution as a function of time 
was measured to create a desupersaturation profile. This profile is considered to be 
directly proportional to the overall growth rate of felodipine. The effectiveness (Eg) of 
HPMCAS was then expressed as a ratio of the measured growth rates 
 !! = !!!!     (4.1) 
  
where R0 and RP represent the growth rate of felodipine in the absence and presence of 
HPMCAS respectively. Therefore, when Eg > 1, the polymer is considered to be effective. 
Felodipine seed crystals were prepared by first melting felodipine crystals, as 
supplied from the manufacturer, and re-crystallizing the melt by exposure to an 
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atmosphere of 75% relative humidity. Seed crystals were mounted on a rotating disc 
apparatus (RDA) which was set to a constant rotational speed, 1000 rpm, to ensure that 
the growth rate coefficent, kG, (equation 1.7) remained constant between experiments.28–
30 A stock solution of 10 mg/mL solubilized felodipine was prepared by dissolving 
felodipine in methanol. Supersaturated aqueous solutions were then generated by adding 
stock solution to pH 6.8 or pH 3 buffer. For felodipine, the equilibrium concentration, C* 
is approximately 0.5 µg/mL at 25°C.31 The initial felodipine solution concentration for 
growth experiments was 4 µg/mL in the absence and presence of 5 µg/mL HPMCAS. 
Stock solutions of 5 µg/mL HPMCAS were generated by dissolving the powder as 
provided in pH 6.8 or pH 3 buffer and mixing for 24 hours. The aqueous solubility of 
HPMCAS is poor at pH 3 compared to pH 6.8. Thus, highly concentrated solutions at pH 
3 appear cloudy. However, at the low HPMCAS concentration used in this study (5 
µg/mL), the solution is clear, indicating the polymer is completely dissolved and does not 
form agglomerates in solution at the experimental concentration.  
 Desupersaturation profiles were measured using a CCD Array UV-vis 
Spectrometer (SI Photonics, Tuscon, AZ) under isothermal conditions (25°C). Data 
collection began immediately after generation of supersaturated solutions. The intensity 
of an absorbance peak of felodipine (wavelength 360) was recorded at 10-second 
intervals for 1 hour. All experiments were performed in triplicate. Calibration solutions, 
prepared in methanol were used to correlate peak intensity to concentration. The slope of 
the resulting concentration v. time curve was recorded as the growth rate, R0 or RP in the 
absence or presence of HPMCAS respectively. 
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4.3.3 Atomic Force Microscopy 
Atomic force microscopy (Figure 2.3) (MultiMode 8 AFM, Bruker Corporation, 
Technology Forest, TX) was used to characterize adsorbed HPMCAS on crystallized 
felodipine. HPMCAS was added to phosphate buffer (0.2mg/mL) and dissolved by 
stirring for up to 24 hours. Seed crystals grown from the melt were exposed to polymer 
solutions using the RDA at 200 rpm for 2 hours.  The surface was not allowed to dry after 
adsorption. Samples were removed from the RDA holder and characterization with AFM 
commenced immediately. Images were taken in fluid using Tapping Mode with NPG-10 
silicon nitride triangular probes (Bruker Corporation, Technology Forest, TX) with 0.24 
N/m spring constant and 30 nm radius of curvature. The scan rate was set to 0.4 Hz and 
scan resolution was set to 512 x 512 pixels2. Characterization was conducted in the same 
liquid as that used for adsorption. For samples characterized at both pH conditions, the 
pH of the medium was increased using sodium hydroxide. No polymers were present in 
the bulk solutions added to the fluid cell during imaging. Height images and phase 
images were taken simultaneously. Incubation times ranged from 3-5 hours. No changes 
in the drug surface were detected over this timeframe. 
 
4.3.4 AFM Coupled with Infrared Spectroscopy 
Infrared images coupled with AFM (Figure 2.4) were obtained using nanoIR 
AFM (Anasys Instruments, Santa Barbara, CA). Images were acquired using C-450 
silicon cantilever probes in contact mode. An OPO nanosecond laser illuminated the 
sample at wavelengths characteristic to felodipine and HPMCAS. Upon irradiation, the 
sample expanded and contracted depending on how much infrared illumination was 
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absorbed, causing the AFM cantilever probe to oscillate a corresponding amount.32 Using 
this approach, IR spectra from sub micron domains can be obtained. IR spectra and 
images were thus obtained by recording the amplitude at various sample locations. IR 
spectra from 1620 to 1800 cm-1 were acquired in increments of 4 cm-1 with 128 laser 
pulses per wavelength. IR images were obtained by irradiating the sample at 1700 cm-1 
and 1720 cm-1 at a scan rate of 0.1Hz.  
 
4.3.5 AFM-IR Sample Preparation 
Samples characterized with AFM-IR were prepared directly on a ZnSe prism. A 
small drop of a 5 mg/mL methanolic solution of felodipine was placed on the prism and 
allowed to evaporate, creating a smooth, thin crystalline film. The method used to adsorb 
HPMCAS to the film was designed to mimic the adsorption method for samples 
characterized with fluid cell AFM. The ZnSe prism was suspended in buffer solution 
containing dissolved HPMCAS at a concentration of 0.2 mg/mL, such that the crystalline 
film was in contact with the solution. The solution was stirred for 1 hour. Upon removal 
from contact with the solution, the prism was dried with nitrogen to remove remaining 
liquid and any HPMCAS that was not adsorbed. 
 
4.4 Results and Discussion 
4.4.1 Polymer Effectiveness 
Plots of felodipine concentration as a function of time in the absence and presence 
of dissolved HPMCAS are shown in Figure 4.2. The slopes of the profiles for pure 
felodipine (R0) and felodipine in the presence of HPMCAS (RP) were measured from the 
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data. Table 4.1 displays the values of R0/RP in order to compare the effectiveness of 
HPMCAS at reducing the growth rate of crystalline felodipine at pH 3 and pH 6.8. While 
R0/RP > 1 at both pH conditions, indicating that growth is reduced, the effectiveness at 
pH 3 is decreased by a factor of about 1.8. A similar trend was observed for ritonavir and 
several carboxylated cellulose polymers.23,33 In these studies, the authors determined that 
the decrease in effectiveness was not due to a decrease in adsorption at the lower pH 
condition. Rather, the authors speculated that the difference in effectiveness might be due 
to changes in polymer conformation. 
 
Figure 4.2. Desupersaturation of felodipine (initial S of 8) in the absence of HPMCAS (♦), and 
in the presence of 5 µg/mL HPMCAS at pH 3 (red !) and pH 6.8 (blue !). Crystal growth rate 
experiments were performed in triplicate, and each data point represents the mean. Error bars 
indicate one standard deviation from the mean. 
Table 4.1. Effectiveness crystal growth rate ratio (Eg = R0/RP) of HPMCAS for felodipine at pH 3 
and pH 6.8. 
pH R0/RP 
3 1.28  
6.8 2.29  
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The pKa of HPMCAS is 5.5, therefore, it is nearly completely ionized at pH 6.8, 
and unionized at pH 3. Based on this information, and the literature previously 
mentioned24–27 it is hypothesized that HPMCAS will be in an extended chain 
conformation at pH 6.8, and form compact coils at pH 3. 
 
4.4.2 Polymer Conformation 
Atomic force microscopy (AFM) was used to analyze the conformation of 
adsorbed HPMCAS on felodipine, and to provide insight into how the conformation 
impacts polymer effectiveness. It should be noted that AFM analysis revealed the same 
felodipine crystal morphology regardless of growth conditions (pH or presence of 
additives), therefore changes to crystal morphology is likely not the cause of changes in 
growth rate.  Figures 4.3a and 4.3b show AFM phase contrast images of the polymer 
adsorbed to the crystal surface at pH 3 and 6.8. A phase contrast image of the pure drug 
with no adsorbed polymer is shown in Figure 4.3c for comparison. Phase contrast 
imaging is sensitive to changes in material properties, such as viscoelasticity,34 making it 
an ideal method for detecting adsorbed polymers.  
 
Figure 4.3. 2µm x 2µm AFM phase images of (a) HPMCAS adsorbed to felodipine at pH 3, (b) 
HPMCAS adsorbed to felodipine at pH 6.8, (c) felodipine with no HPMCAS adsorbed. Images 
were captured in liquid at room temperature with an incubation time of about 3 hours. 
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The results qualitatively confirm differences in HPMCAS conformation at the 
solid-liquid interface as a function of pH. The dark spots in Figure 4.3a are evidence of 
distinct globules of HPMCAS adsorbed to the crystalline drug surface at pH 3. In contrast, 
at pH 6.8, the AFM reveals dark shading (Figure 4.3b), over the entire surface. This dark 
shading is not present in the image of pure drug (Figure 4.3c), thus it is indicative of 
extended polymer chains dispersed across the drug surface. These results are in 
qualitative agreement with the proposed hypothesis. Specifically, the adsorbed polymer, 
when ionized, extends itself across the surface in order to isolate the charges present on 
its functional groups, while the unionized polymer does not suffer from internal 
electrostatic repulsion and can remain coiled. 
 Quantitative analysis of the topography of HPMCAS adsorbed to felodipine at 
both pH conditions can provide insight into how these changes in conformation impact 
the effectiveness of HPMCAS. Cross sections of the surface topography at both pH 
conditions are presented in Figure 4.4. The cross section of the surface at pH 6.8 (Figure 
4.4a), reveals a relatively even height distribution and small topographical features up to 
about 0.8nm in height. The molecular diameter of glucose (an approximate surrogate for 
the monomer units of HPMCAS) is about 0.75 nm, which is consistent with these height 
variations. Thus it can be deduced that the polymer chains lay parallel to the surface, and 





Figure 4.4. AFM cross-sectional height analyses of HPMCAS adsorbed to felodipine at (a) pH 
6.8, revealing a relatively even height distribution, and at (b and c) pH 3 illustrating sample 
globule dimensions and standard distances between adjacent globules. AFM images were 
captured in liquid at room temperature with an incubation time of 3-5 hours. 
 
 
Figure 4.4b shows a cross section of the surface at pH 3. Instead of many small 
topographical features, one large feature is present which has a radius of about 17 nm and 
a height of about 2 nm, providing an example of the size and shape of the adsorbed 
polymer globules at pH 3. The average radius, rp, of all globules present on a 1.5µm x 
1.5µm area was determined to be 15.4 nm using ImageJ analysis35 as shown in Figure 4.5. 
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The average polymer globule height, hp, was found to be 2.98 nm using cross-sectional 
analysis. These dimensions were applied to determine the average globule volume by 
modeling the globule as a spherical cap:36  
 V = !!!h!(3r!! + h!!)   (4.2) 
 
From this equation, the average globule volume was determined to be 1.05x10-3 
nm3. Given this volume as well as the polymer density and molecular weight provided by 
the manufacturer, it was determined that an average of ~46 HPMCAS molecules were 
present in each globule. 
Figure 4.4c provides an illustration of the distance between globules on the 
crystalline drug surface at pH 3, whereby it can be seen that the distance between any two 
globules ranged from 25-50 nm. Further analysis using ImageJ (Figure 4.5) revealed the 
average distance between globules to be about 44 nm.  
 
Figure 4.5. ImageJ analysis of HPMCAS adsorbed to felodipine at pH 3. Analysis reveals 




These results provide a mechanistic understanding of the role of polymer 
conformation on growth inhibition. The fact that multiple polymer molecules are present 
in each globule at pH 3 explains why polymer adsorption did not decrease at the lower 
pH condition in the study by Ilevbare et al. previously mentioned.23 The key 
consideration is the large distance between globules at pH 3. These spaces between 
globules leave a large number of felodipine growth sites open and available for growth 
units to attach; the molecular diameter of a felodipine molecule is about 0.9 nm, which is 
approximately 50 times smaller than the determined average distance between globules. 
From equations (1.15) and (1.13c), it is clear that as this average distance between 
globules, l, increases, the ratio RP/R0 increases. Thus, the effectiveness factor, Eg 
(equation 4.1) will be reduced at pH 3, which agrees with the results displayed in Figure 
4.2 and Table 4.1. Conversely, the extended polymer chain conformation observed at pH 
6.8 should have the ability to block more than one growth site, either by adsorbing to 
multiple sites, or by creating a barrier for growth units attaching to neighboring sites due 
to the extension of the chain, rendering it more effective at pH 6.8. 
 To determine if adsorbed polymer conformation is reversible, HPMCAS was 
adsorbed to felodipine at pH 3, and the topography was immediately characterized with 
AFM in pH 3 solution. The pH of the solution over the sample was then increased to pH 
6.8 and the topography of the same location on the sample was characterized again. The 
results, displayed in Figure 4.6, show a change upon increasing the pH. At pH 3, the 
coiled polymer chains, are revealed as distinct spots in Figure 4.6a. Despite the presence 
of less obvious spots in the phase image at pH 6.8 (Figure 4.6b), the corresponding 
topographical scan at pH 6.8 (Figure 4.6d) reveals that the polymers are no longer 
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arranged in a compact globular formation. This change in conformation is especially 
clear when compared to the topography at pH 3 (Figure 4.6c).  
 
 
Figure 4.6. (a) 2µm x 2µm AFM phase image and (c) corresponding 3D height image 
topography of HPMCAS adsorbed to felodipine at pH 3. (b) AFM phase image and (d) 
corresponding 3D height image topography of the same area after the pH of the system was 




Computation of the root mean square roughness of a 1.5µm x 1.5µm area at both 
pH conditions reveal a 29.3% decrease in surface roughness at pH 6.8 compared to pH 3. 
This quantitatively confirms that the polymer chains are no longer coiled when the pH is 
increased to 6.8. Polymer adsorption is considered to be irreversible, however, it is 
possible that after the pH increases, polymer chains that were previously coiled in a 
globule but not adsorbed will diffuse into the bulk solution and adsorb elsewhere on the 
surface. However, the phase image at pH 6.8 (Figure 4.6b) reveals dark spots, unlike 
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Figure 4.3b. It can be deduced that these spots in Figure 4.6b represent a large density of 
extended polymer chains in the location of the pre-existing globules. This result suggests 
that when the polymers become ionized and extend, it is not likely that they migrate away 
from their original cluster to open growth sites on the surface within the timeframe of 
these experiments. Rather, they extend to occupy growth sites in the local vicinity of their 
original deposition coordinate.  
 To summarize, the conformation of HPMCAS adsorbed on a crystalline 
felodipine surface is pH-dependent. At pH 6.8, above its pKa, HPMCAS is ionized, 
therefore its functional groups will self-repulse and the polymer chains will extend. This 
has a favorable effect on the polymer’s ability to inhibit crystal growth because it allows 
for more extensive growth site coverage for a given mass of deposited polymer. At pH 3, 
below its pKa, HPMCAS is unionized, and the polymer chains remain coiled due to 
intramolecular bonding. It is now known that multiple coils will combine, forming 
globules on the surface of the drug. This has an unfavorable impact on the polymer’s 
ability to inhibit crystal growth because it leaves growth sites vacant for drug growth 
units to attach. 
 
4.4.3 Chemical Identification of Polymer Adsorption 
To confirm chemically that HPMCAS adsorbs to felodipine, the drug was 
characterized with infrared spectroscopy coupled with AFM (AFM-IR) before and after 
exposure to HPMCAS in solution at pH 6.8. Due to the nature of the measurement, 
samples could not be characterized in liquid. Following polymer adsorption, the surface 
was dried with nitrogen resulting in agglomeration of HPMCAS molecules on the surface, 
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as revealed by the large aggregates in the topographical image (Figure 4.7). Therefore it 
should be noted that AFM-IR experiments were completed for the purpose of chemical 
characterization only, not to gain any conformational information. The corresponding 
color-coded spectra in Figure 4.7 reveal that the large agglomerates on top of the smooth 
drug layer exhibit an absorbance peak at 1720 cm-1 (green and black) which arises from 
the carbonyl group found in HPMCAS, confirming that the aggregates are polymer. In 
contrast, spectra taken at various positions on what is expected to be the pure drug layer 
(blue and red) do not have a peak at 1720 cm-1, but do exhibit four absorbance peaks 
from 1650 – 1700 cm-1, which arise from felodipine functional groups. The spectra taken 
on the HPMCAS agglomerates also show absorption bands from 1650 – 1700 cm-1, 
characteristic of felodipine. The presence and reduced height of these peaks can be 
attributed to the fact that the IR laser must pass through the drug layer underneath 
adsorbed HPMCAS. Thus, at these locations, the sample exhibited absorbance at the 
characteristic drug frequencies in addition to the characteristic polymer frequency. 
However, the presence of adsorbed HPMCAS considerably dampened the signal arising 
from the drug that reached the AFM tip.  
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Figure 4.7.  AFM-IR spectra from 1620-1800 cm-1 of felodipine (red and blue) and HPMCAS 
adsorbed to felodipine (green and black), and their corresponding locations on the AFM height 
image. 
 
 Figure 4.8 shows the chemical images captured as the sample was selectively 
illuminated at 1700 cm-1 and 1720 cm-1, wavenumbers characteristic of felodipine and 
HPMCAS respectively. Pure felodipine was characterized prior to HPMCAS adsorption 
(Figure 4.8a). Illumination at 1700 cm-1 reveals a uniform absorbance at this wavelength, 
as expected for a chemically homogeneous surface. The sample was illuminated again at 
1700 cm-1 after exposure to HPMCAS. The result, Figure 4.8b, now reveals dampened 
absorptivity (purple) when the AFM tip encountered a polymer agglomerate. This same 
area was irradiated at 1720 cm-1, (Figure 4.8c), and it is immediately clear that the 
resulting image is the inverse of that shown in Figure 4.8b. There was strong absorptivity 
(orange) when the tip encountered a polymer agglomerate, and little absorptivity at this 
wavenumber on the drug crystal surface. The absence of signal from some of the smaller 
HPMCAS features in Figure 4.8c is due to the lesser thickness of these small 
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agglomerates compared to the drug layer. Since the IR laser passes through both layers, 




Figure 4.8. 5µm x 5µm AFM-IR chemical images of (a) pure felodipine illuminated at 1700 cm-
1 (b) felodipine after exposure to HPMCAS illuminated at 1700 cm-1 and (c) 1720 cm-1. 
 
 
 These results provide clear evidence that HPMCAS adsorbs to felodipine under 
the conditions specified in the current study. After exposure to HPMCAS, agglomerates 
were present on the felodipine surface, whereby submicron chemical imaging confirmed 
the chemical identity of the agglomerates.  
 
4.5 Conclusions 
When the moderately hydrophobic carboxylated cellulose polymer, HPMCAS, was 
not ionized in aqueous solution, it was found to adsorb onto the surface of crystalline 
felodipine in the form of compact coils resulting in distinct polymer globules with poor 
total surface coverage. In contrast, when ionized, HPMCAS chains extended, presumably 
due to charge repulsion between molecules, resulting in a more uniform surface coverage. 
In concert, it was noted that the inhibitory effect of HPMCAS on the solution crystal 
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growth of felodipine was considerably diminished at a low pH when the polymer is not 
ionized relative to at a higher pH when the polymer is ionized. Thus it is apparent that the 
reduced inhibitory impact of the polymer on crystal growth at low pH arises from the 
globule formation which leaves many growth sites available on the crystal; in contrast 
more growth sites are blocked when the polymer is more evenly distributed on the 
surface as a consequence of repulsive interactions and growth rate is more effectively 
reduced. The insights gained from this study with felodipine and HPMCAS can be 
applied to other drug-polymer systems, and can be used to identify polymers which both 
adsorb to the crystal surface and provide a high degree of surface coverage. This will 
ultimately improve the delivery of poorly water soluble therapeutics, which rely on the 








 Several crystallographic planes were identified as being present on the 
recrystallized amorphous films, as determined by measuring the angles between the faces 
(Figure 4.9 and Table 4.2). Polymer adsorption was observed, for example, on the (1 1 -
1), (1 -2 -2), and (1 -1 1) faces. Each of these faces presents a different surface chemistry 
(Figures 4.10 – 4.12), with potential exposure of multiple functional groups including 
methyl, chlorine, and oxygen atoms. No difference could be discerned in the density of 
HPMCAS adsorption between these three faces, suggesting that adsorption is nonspecific. 
 
Figure 4.9. 2µm x 2µm AFM phase image of HPMCAS adsorbed to a felodipine crystallite at pH 
3. The crystallite was formed following recrystallization of the amorphous material by exposure 
to buffer solution. The image reveals that HPMCAS adsorbs with comparable density to multiple 
crystal faces. The corresponding crystallographic planes were determined from the angles 





Table 4.2. The measured angles between faces of the felodipine single crystal shown in Figure 
4.9, compared to the predicted angles between crystallographic planes. Angles were measured 
from the corresponding AFM height image using cross sectional analysis. Small discrepancies 
between measured and predicted values are due to instrument error and limitations of the top-
down cross sectional analysis method. 
 
Angle Measured with AFM Predicted 
A 100.1° 97.66° 
B 87.6° 86.8° 
C 75.5° 75.66° 
D 103.5° 103.23° 
 
 
Figure 4.10. Surface chemistry of the (1 1 -1) face. Methyl groups and oxygen atoms are exposed 
at the surface. 
 
 
Figure 4.11. Surface chemistry of the (1 -1 1) face. Chlorine atoms and methyl groups are 




Figure 4.12. Surface chemistry of the (1 -2 -2) face. Methyl groups, amine groups, and oxygen 
atoms are exposed at the surface. The varying surface chemistry between this face and the (1 1 -1) 
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CHAPTER 5. INFLUENCE OF POLYMERS ON THE CRYSTAL GROWTH RATE 
OF FELODIPINE: CORRELATING ADSORBED POLYMER SURFACE 
COVERAGE TO SOLUTION CRYSTAL GROWTH INHIBITION 
This chapter is a reprint with minor modifications of a manuscript published in Langmuir 
in September 2015 with the same title by: Caitlin J. Schram, Lynne S. Taylor, and 
Stephen P. Beaudoin. 
 
5.1 Abstract 
The bioavailability of orally administered drugs that exhibit poor aqueous 
solubility can be enhanced with the use of supersaturating dosage forms. Stabilization of 
these forms by preventing or inhibiting crystallization in solution is an important area of 
study. Polymers can be used to stabilize supersaturated systems, however the properties 
that impact their effectiveness as crystal growth rate inhibitors are not yet fully 
understood. In this study, the impact of various polymers on the crystal growth rate of 
felodipine and the conformation of these polymers adsorbed to crystalline felodipine was 
investigated in order to gain a mechanistic understanding of crystal growth inhibition. It 
was determined that polymer hydrophobicity impacted polymer adsorption as well as 
adsorbed polymer conformation. Polymer conformation impacts its surface coverage, 
which was shown to directly correlate to the polymer’s effectiveness as a growth rate
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 inhibitor. By modeling this correlation, it is possible to predict polymer 
effectiveness given the surface coverage of the polymer.   
 
5.2 Introduction 
The crystal form of a compound can greatly impact its physical, chemical, and 
mechanical properties. Therefore, the ability to manipulate crystallization from 
supersaturated solutions is of importance to many industries. In the pharmaceutical field, 
controlling crystal formation is fundamental to optimizing drug formulation and 
delivery.1 In particular, there is growing interest in slowing or inhibiting crystallization of 
organic molecules using polymeric additives.2–4  
The ability to inhibit crystallization is desirable because nearly 80% of 
investigational drugs have suboptimal aqueous solubility.5 Formulating a drug as an 
amorphous solid can result in increased dissolution rates and the generation of a 
supersaturated solution.6–8 In this form, the drug will permeate across gastrointestinal (GI) 
tract membranes at a faster rate, thereby greatly increasing absorption.9,10 A major 
challenge to the utilization of supersaturating delivery systems, however, is the difficulty 
in maintaining supersaturation, because of the driving force for crystallization.11,12 Thus, 
preventing crystallization to maintain supersaturation is crucial to increasing drug 
exposure.  
Additives, such as polymers can inhibit crystallization and stabilize supersaturated 
solutions.13 While many studies have been conducted to identify effective polymers, the 
key properties that render a polymer effective are not widely understood. Several recent 
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studies determined that polymer hydrophobicity can greatly impact effectiveness,3,14,15 
however the explanation for this phenomenon has not yet been determined.  
The objective of this study was to investigate the adsorbed conformation of a 
group of polymers of varying hydrophobicity on the surface of crystalline drug, and the 
corresponding effect of this adsorption on crystal growth. A polymer’s adsorbed 
conformation has been shown to influence its ability to inhibit crystal growth.16 Therefore, 
it is hypothesized that polymer hydrophobicity will greatly impact adsorbed polymer 
conformation, consequently influencing the effectiveness as a growth inhibitor.  
 
5.3 Experimental Section 
5.3.1 Materials 
Felodipine was provided by Attix (Toronto, Ontario, Canada). Methanol (HPLC 
grade) was purchased from Avantor Performance Materials (Center Valley, PA). The 
polymers used in this study were hydroxypropylmethyl cellulose acetate succinate 
(HPMCAS) LF grade, Mw 18 000 g mol-1 and hydroxypropylmethyl cellulose (HPMC) 
606 grade (Shin-Etsu Chemical Co, Ltd., Tokyo, Japan), polyvinylpyrrolidone (PVP), Mw 
40 000 g mol-1, polyacrylic acid (PAA) Mw 450 000 g mol-1, and poly(vinyl pyrrolidone 
vinyl acetate) (PVPVA), Mw 50 000 g mol-1 (Sigma-Aldrich Co., St. Louis, MO), and 
poly(2-vinylpyridine) (P2VP), Mw 40 000 g mol-1  and polyvinyl acetate (PVAc), Mw 90 
000 g mol-1  (Polysciences Inc., Warrington, PA). The crystallization and adsorption 
media used in all experiments was 50 mM pH 6.8 phosphate buffer.  The chemical 
structures of felodipine and the polymers used in this study are given in Figure 2.5. 
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5.3.2 Crystal Growth Rate Measurements 
The growth rate of felodipine was measured in the absence and presence of the 
polymers shown in Figure 2.5. The concentration of felodipine in solution as a function 
of time was measured to determine a desupersaturation profile. This profile is considered 
to be directly proportional to the overall growth rate of felodipine. The effectiveness (Eg) 
of each polymer can then be expressed as a ratio of the measured growth rates 
 !! = !!!!     (5.1) 
  
where R0 and RP represent measured growth rates of felodipine in solution in the absence 
and presence of polymer respectively. Therefore, when Eg > 1, the polymer is considered 
to be effective. 
Felodipine seed crystals were prepared by first melting felodipine crystals, as 
supplied from the manufacturer, in a custom PTFE holder and re-crystallizing the melt by 
exposure to an atmosphere of 75% relative humidity. This yielded a flat surface of well-
defined and consistent surface area. Seed crystals in the holder were mounted on a 
rotating disc apparatus (RDA) (Princeton Applied Research, model 616), which was set 
to a constant rotational speed, 6000 RPM, to ensure that the measured growth rate was 
independent of mass transfer and reflected the rate of integration only. A stock solution 
of 10 mg/mL solubilized felodipine was prepared by dissolving felodipine in methanol. 
Supersaturated aqueous solutions were then generated by adding a small amount of the 
felodipine stock solution to pure pH 6.8 buffer, or buffer containing pre-dissolved 
polymers. The initial solution concentration for growth experiments was 2 µg/mL. The 
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equilibrium concentration of felodipine is approximately 0.5 µg/mL at 25°C,17 thus the 
experiments were carried out at initial S = 4. Polymers were pre-dissolved in pH 6.8 
buffer to create stock solutions with concentrations of 5 and 10 µg/mL. 
 Desupersaturation profiles were measured using a CCD Array UV-vis 
Spectrometer (SI Photonics, Tuscon, AZ) under isothermal conditions (25°C). Data 
collection began immediately after generation of supersaturated solutions. The intensity 
of an absorbance peak of felodipine (wavelength 238 nm) was recorded at 10-second 
intervals for 1 hour. All experiments were performed in triplicate. Calibration solutions, 
prepared in methanol were used to correlate peak intensity to concentration. The slope of 
the resulting concentration v. time curve was recorded as the growth rate, R0 or RP in the 
absence or presence of polymers.  
 
5.3.3 Atomic Force Microscopy 
Atomic force microscopy (Figure 2.3) (MultiMode 8 AFM, Bruker Corporation, 
Technology Forest, TX) was used to characterize adsorbed polymers on crystallized 
felodipine. Seed crystals grown from the melt were exposed for two hours to the same 
polymer stock solutions used for growth experiments. Samples were removed from the 
RDA holder and characterization with AFM commenced immediately. The surface was 
not allowed to dry after adsorption, and images were taken in the same liquid as that used 
for the adsorption step. Characterization was done using Tapping Mode with NPG-10 
(0.24 N/m spring constant, 30 nm radius of curvature) or SNL-10 (0.24 N/m spring 
constant, 10 nm radius of curvature) silicon nitride triangular probes (Bruker Corporation, 
Technology Forest, TX). The scan rate was set to 0.4 Hz and scan resolution was set to 
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512 x 512 pixels2. Height images and phase contrast images were obtained 
simultaneously. Phase contrast imaging is sensitive to changes in material properties, 
such as viscoelasticity,18 thus it is an ideal method for detecting adsorbed polymers. 
 
5.3.4 Determination of Polymer Surface Coverage 
AFM phase contrast images were analyzed using ImageJ19. Each image was 
converted to an 8-bit bichromatic image such that polymers stood out as black objects on 
a white background. The threshold limits were set to be consistent between all systems 
such that the analysis could eliminate felodipine surface effects and accurately represent 
the size of polymers as shown in the phase contrast images. The software could then 
determine the percentage of the image area occupied by black pixels.  
 
5.3.5 Contact Angle Measurements 
Contact angle measurements of DI water and ethylene glycol on a crystalline 
felodipine surface were taken in order to determine the surface energy of felodipine. 
Measurements were taken under ambient conditions using a Ramé-Hart model 500 
goniometer and DROPimage advanced software. Ten drops were measured for each 
liquid, and a total of ten measurements were taken per drop in order to obtain an average 
contact angle for each of the two liquids on felodipine. The surface energy was then 
estimated using the harmonic mean approach, or two liquid method proposed by Wu.20 
This approach uses the harmonic mean of the disperse and polar components of both the 
liquid and solid surface tensions to determine the solid-liquid interfacial tension. The 
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surface energy can then be determined from the calculated interfacial tension and 
measured contact angles using Young’s equation.21 
 
5.3.6 Determination of Felodipine Growth Unit Size 
The size of a felodipine growth unit was determined using the crystal structure 
visualization software, Mercury.22 The molecular structure of felodipine (form DONTIJ) 
was provided by the Cambridge Crystallographic Data Centre (CCDC) structural 
database. The measure distances tool in Mercury was used to determine the length and 
width of a felodipine molecule. These measurements were used to calculate the area 
occupied by a growth unit on a crystal surface. 
 
5.4 Results and Discussion 
Polymer adsorption to a solid-liquid interface is driven by energetically favorable 
interactions between the polymer and solid as influenced by the medium. In short, 
whether or not a polymer will adsorb to a solid is determined by how favorably the 
polymer interacts with the solid compared to how favorably it interacts with the solvent.23 
In a poor solvent, the polymer will want to escape the medium and will consequently 
adsorb to the surface.24 However, even in a good solvent, a polymer will adsorb if it 
forms more favorable intermolecular interactions with the solid than with the solvent. 




5.4.1 Impact of Polymer Hydrophobicity on Adsorption 
The crystal growth rate of pure felodipine (R0) and the growth rate of felodipine 
in the presence of polymers (RP) were measured to determine the growth rate ratio, R0/RP, 
which indicates polymer effectiveness (equation 5.1). The results are shown in Figure 5.1, 
arranged in order of increasing polymer hydrophobicity. The order was determined from 
previously published solubility parameters calculated for each polymer.25  
 
 
 Figure 5.1. Effectiveness crystal growth rate ratio of felodipine at initial S of 4 with various 
polymers present at a concentration of 5 µg/mL. Growth rate experiments were performed in 
triplicate and each column represents the mean. Error bars indicate standard error of the mean. 
 
Figure 5.1 shows that polymer hydrophobicity plays an important and complex 
role in polymer effectiveness. The very hydrophilic and hydrophobic polymers are 
relatively ineffective (Eg ~1-1.5), whereas the moderately hydrophobic polymers are two 
to three times more effective. A similar trend was observed in a previous study for the 
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API ritonavir.15 In this study, the authors hypothesized that polymer hydrophobicity may 
affect the extent of adsorption of polymer to the drug.  
 To test this hypothesis, each polymer was adsorbed to felodipine and 
subsequently analyzed with atomic force microscopy (AFM). The results for select 




Figure 5.2. 750 nm x 750 nm AFM height and corresponding phase contrast images of felodipine 
after exposure to (a) PAA, (b) PVP, (c) HPMCAS, and (d) PVAc, and (e) pure felodipine with no 
exposure to polymers. Images were captured in liquid at room temperature with an incubation 
time of 4-5 h. 
 
The very hydrophilic polymer PAA (Figure 5.2a) shows no evidence of 
adsorption to crystalline felodipine. This explains why PAA has no effect on the growth 
rate of felodipine (R0/RP = 1). Very hydrophilic polymers such as PAA interact favorably 
with water; therefore PAA has little driving force to adsorb to the drug surface.  At the 
other end of the spectrum, PVAc, a very hydrophobic polymer, shows evidence of 
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adsorption (Figure 5.2d), however, it adsorbs in aggregates. This can be seen from the 
dark spots in the phase image as well as the raised globules in the corresponding 3D 
height image. A similar result was observed by Amiel et al. for hydrophobic polymers.26 
This result suggests that hydrophobic polymers such as PVAc are driven to adsorb to the 
drug surface in order to minimize interactions with water. The adsorbed aggregated 
conformation also reflects the polymer’s desire to minimize surface contact with water. 
Therefore, although PVAc is present on the drug surface, the poor surface coverage due 
to aggregation results in poor growth rate inhibition as shown in Figure 5.1. 
 Of the four systems shown, HPMCAS, which is a moderately hydrophobic 
polymer, adsorbs with the highest degree of surface coverage, as evidenced by the 
relatively uniform dark shading in the AFM phase image (Figure 5.2c). This result 
suggests that HPMCAS has a certain hydrophilic/hydrophobic balance necessary to not 
only drive adsorption to the surface but to interact favorably with both the drug and the 
aqueous medium once adsorbed. The height image reveals no obvious surface features, 
suggesting that HPMCAS chains are spread fairly flat on the surface. This was shown to 
be the case for HPMCAS at pH 6.8 in Chapter 4. Because HPMCAS contains both 
hydrophobic and hydrophilic functional groups and favorably interacts with both the 
aqueous medium and the more hydrophobic drug surface, it provides a high degree of 
surface coverage, and is a more effective growth rate inhibitor (Figure 5.1).  
 Although PVP is a very hydrophilic polymer, AFM characterization reveals that it 
adsorbs to felodipine (Figure 5.2b). This suggests that PVP adsorption to felodipine may 
be driven by specific interactions between the polymer and drug. Previous studies have 
provided evidence of PVP adsorption due to hydrogen bonding.14,27,28 Karavas et al. 
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confirmed that PVP interacts with felodipine via a hydrogen bond, which forms between 
the carbonyl group of PVP and the amino group of felodipine.29 In fact, their results 
indicated that PVP forms two specific interactions with felodipine. The second 
interaction could be formed with the amide group of PVP.30 
It is possible that the adsorption of PVP to felodipine is due in part to 
hydrophobic effects as well. PVP has been known to adsorb to hydrophobic surfaces, 
such as graphite in water. According to Esumi et al., graphite preferentially interacts with 
PVP over water due to the solid’s hydrophobic nature.31 Thus, PVP adsorption to 
graphite is not a result of poor polymer-solvent interactions, but due to unfavorable 
surface-solvent interactions. This effect could contribute in concert with hydrogen 
bonding to the adsorption of PVP on hydrophobic felodipine. 
  Although PVP adsorbs to felodipine, it has limited impact on the growth rate 
(Figure 5.1) due to its aggregated conformation (Figure 5.2b). This conformation is a 
result of hydrophobic effects. The hydrophilic polymer forms aggregates in order to 
minimize contact with the hydrophobic drug surface.32  
In summary, the results indicate that polymer hydrophobicity is an important 
factor which influences polymer effectiveness due to its impact on adsorption and 
adsorbed polymer conformation. Very hydrophilic polymers will likely not adsorb 
because they prefer to remain in solution. As polymer hydrophobicity increases, it is 
more likely to interact with the drug in order to minimize contact with the aqueous 
solution. Polymer hydrophobicity also impacts the polymer’s adsorbed conformation. 
Very hydrophobic polymers will aggregate to minimize interactions with the aqueous 
medium whereas more hydrophilic polymers will aggregate to minimize contact with the 
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hydrophobic drug surface. Polymers with intermediate hydrophobicity will interact 
favorably with both the medium and the drug surface, resulting in a spread out 
conformation. These variations in conformation impact the polymer surface coverage, 
which influences growth rate inhibition. 
In Figure 5.1, the growth rate results of felodipine with PVPVA, the random co-
polymer of PVP and PVAc, reveal that PVPVA is a better growth rate inhibitor than the 
same concentration of either PVP or PVAc alone. This is most likely because PVPVA 
has a higher net driving force for adsorption than PVP or PVAc alone. PVPVA 
adsorption to felodipine is driven by the combination of hydrophobic interactions (PVAc 
units) and specific interactions (PVP units), resulting in greater overall surface coverage.  
Greater surface coverage by PVPVA suggests that PVP and PVAc may adsorb to 
different felodipine sites. To gain more insight into this, crystal growth rates were 
measured in the presence of a polymer mixture composed of equal parts PVP and PVAc 
at two different concentrations. The results are displayed in Figure 5.3 along with the 




Figure 5.3. Effectiveness crystal growth rate ratio of felodipine at initial S of 4 with various 
polymers present at a total polymer concentration of 5 or 10 µg/mL. Growth rate experiments 
were performed in triplicate and each column represents the mean. Error bars indicate standard 
error of the mean. 
 
The results indicate that the polymer mixture at both 5 and 10 µg/mL total 
concentrations have the same effect on the growth rate of felodipine as the copolymer. 
The fact that the polymer mixture is also able to achieve greater coverage than the same 
concentration of PVP or PVAc alone suggests that PVP and PVAc are able to bind to 
different felodipine sites and do not necessarily compete for equally energetic sites on the 
surface.  
 
5.4.2 Polymer Surface Coverage 
To determine the surface coverage of each polymer adsorbed to felodipine, Φ, 
samples were characterized with AFM phase imaging. It should be noted that the surface 
coverage is a physical parameter that describes simply the macroscopic fraction of the 
felodipine surface covered by polymer, while θ, the fractional coverage as defined by the 
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Kubota-Mullin model (equation 1.15), represents the ratio of the average distance 
between sites available for impurity adsorption to the average distance between adsorbed 
impurities (as described in equation 1.13c).  While these parameters may be proportional, 
they are not identical.  The AFM images were then analyzed using ImageJ analysis.19 The 
results are presented in Figure 5.4 in order of increasing polymer coverage. Table 5.1 




Figure 5.4. 750 nm x 750 nm AFM phase images and corresponding ImageJ analysis images of 
(a) PVP, (b) P2VP, (c) PVAc, (d) PVPVA, (e) PVP + PVAc (10 µg/mL), (f) PVPVA (10 µg/mL), 
(g) HPMCAS, (h) HPMC adsorbed to crystalline felodipine. Polymer solution concentrations 
were 5 µg/mL unless otherwise indicated. AFM images were captured in liquid at room 
temperature with an incubation time of 4-5 h. 
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Table 5.1. Fractional surface coverage values for each polymer adsorbed to felodipine 




PVP 0.08 ± 0.008 
P2VP 0.10 ± 0.014 
PVAc 0.14 ± 0.007 
PVPVA 0.19 ± 0.025 
PVP + PVAc (10 µg/mL) 0.28 ± 0.021 
PVPVA(10 µg/mL) 0.31 ± 0.018 
HPMCAS 0.53 ± 0.025 
HPMC 0.54 ± 0.008 
 
These results, when compared to the growth rate results presented in Figures 5.1 
and 5.3, indicate that there is a correlation between polymer coverage and polymer 
effectiveness. The polymers that adsorb with higher coverage are the most effective 
growth rate inhibitors, and polymers that adsorb with the lowest coverage are less 
effective.  Plotting polymer effectiveness, R0/RP, as a function of fractional surface 
coverage (Figure 5.5) reveals that there is a linear correlation between polymer coverage 





Figure 5.5. Plot of crystal growth rate ratios (polymer effectiveness) as a function of fractional 




5.4.3 Modeling the Correlation between Growth Rate and Polymer Coverage 
According to the Kubota-Mullin model, a greater fractional coverage by the 
polymer, θ, will result in a reduced growth rate when polymer is present, RP, as shown in 
equation (1.15).  As mentioned above, the definition of fractional coverage expressed in 
the model, θ, is the ratio of the average distance between available sites for adsorption 
and the average distance between adsorbed polymers. This is different from the definition 
of polymer surface coverage, Φ, which is a parameter that is determined experimentally.  
However the two parameters are expected to be proportional. Modeling the experimental 
results using the Kubota-Mullin model can confirm this proportionality. 
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Equation (1.15) can be applied in the current study because the first condition 
given in Section 1.5 is satisfied by the fact that seed crystals were grown in a holder of 
constant area for all experiments. The second condition is assumed to be true based on 
observations made with atomic force microscopy. There was no noticeable difference in 
surface area of the individual felodipine faces for the imaged systems with adsorbed 
polymer compared to the pure drug system. Thus, equations (1.15), (1.13b), and (1.13c) 
were combined to give the following expression: 
 
!!!! = 1− !"!!!(!"#)(!") !   (5.2) 
 
The value of each parameter, except the average distance between adsorbed polymers, l, 
was known or experimentally determined. The values of these constants are given in 
Table 5.2. Temperature supersaturation, S, were determined from the experimental 
conditions. The size of a felodipine growth unit, a, was determined using the crystal 
structure visualization software Mercury,22 as explained in section 5.3.6. To determine 
the surface energy of crystalline felodipine, !, the contact angles of two different liquids 
on a crystalline felodipine surface were measured with a goniometer. ! was then 
calculated from the measured contact angles using the harmonic mean approach20 as 






Table 5.2. Values used in equation (5.2) 
Constant Parameter Value ! 3.9E-20 J/nm 
a 0.584 nm2 
k 1.38E-23 J/K 
T 298.15 K 
lnS 1.39 
 
The average distance between polymers, l, varies for each system and is 
dependent on polymer surface coverage. Thus, it was necessary to determine a 
relationship between l and Φ. Values of l for all polymer systems except PVPVA at 
initial concentration 10 µg/mL were fitted to equation (5.2) to minimize the residual error 
at each value of Φ such that the experimental and theoretical values of R0/RP converged. 
These fitted values for l were then plotted against Φ as shown in Figure 5.6, resulting in 
the power relation given in equation (5.3). 
 
 
Figure 5.6. Values determined for the average distance between polymers plotted against Φ. 
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 ! = 4.13Φ!!.!!   (5.3) 
 
With this general expression to relate l and Φ, the unknown parameter, l, in 
equation (5.2) can be determined from the measured surface coverage. Substituting this 
relation into equation (5.2) for l produces the theoretical values for R0/RP plotted in 
Figure 5.7. It can be seen that by using this model, the theoretical values for R0/RP are in 
good agreement with the experimental values. 
 
 
Figure 5.7. Plot comparing experimental R0/RP values (red !) to theoretical R0/RP values (blue ♦) 
determined using the Kubota-Mullin model, and the predicted effectiveness of 10 µg/mL PVPVA 
("). 
 
 The agreement between experimental and theoretical results suggests that the 
model should be able to predict polymer effectiveness given the AFM determined 
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fractional coverage of the polymer. To demonstrate the predictive ability of the model, 
the equation of the best-fit line for the linear theoretical relationship was determined to be  
 
!!!! != !3.918Φ!+ !1    (5.4) !
Entering the experimentally determined Φ for PVPVA (initial concentration 10 
µg/mL) adsorbed to felodipine into equation (5.4) results in a predicted R0/RP value, 
which is in good agreement with the experimental value (Figure 5.7). This suggests that a 
polymer’s effectiveness can be accurately predicted using this model.   
 In summary, the results shown in Figure 5.7 provide clear evidence that there is a 
linear correlation between polymer effectiveness (R0/RP) and polymer surface coverage. 
This correlation can be modeled using the Kubota-Mullin model whereby the distance 
between polymers depends on the polymer surface coverage according to the relation 
given in equation (5.3). Thus, using this model, polymer effectiveness can be accurately 
predicted if the polymer surface coverage is known.  
 
5.5 Conclusions 
In this study, the ability of a group of polymers with varying hydrophobicity to 
inhibit the crystal growth rate of felodipine in aqueous solution was assessed. The results 
indicated that moderately hydrophobic polymers were two to three times more effective 
than the very hydrophilic or very hydrophobic polymers. It was concluded that polymer 
hydrophobicity drives adsorption and also impacts adsorbed polymer conformation. In 
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addition, polymer fractional surface coverage was shown to correlate linearly to polymer 
effectiveness. This correlation can be modeled using the Kubota-Mullin model, and used 
to predict polymer effectiveness when surface coverage is known.  
The results of this study provide a better mechanistic understanding of the process 
by which polymers can effectively inhibit crystal growth. Specifically, they demonstrate 
that surface coverage due to adsorbed conformation is a critical determinant of 
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CHAPTER 6. POLYMER INHIBITION OF CRYSTAL GROWTH BY SURFACE 
POISONING 
This chapter is a preprint with minor modifications of a manuscript submitted to Crystal 
Growth & Design with the same title by: Caitlin J. Schram, Stephen P. Beaudoin, and 
Lynne S. Taylor. 
 
6.1 Abstract 
Controlling the rate of crystal growth from supersaturated solutions is a desirable 
capability in the pharmaceutical field. The biological absorption of poorly-soluble drugs 
can be enhanced by inhibiting crystal growth and prolonging the duration of 
supersaturated solutions formed in vivo by dissolving supersaturating dosage forms. The 
use of polymeric additives to slow crystal growth is an emerging area of interest, yet the 
mechanisms of polymer inhibition are still being explored. In this study, the ability of a 
polymer to poison crystal growth and impact crystal morphology is assessed for 
felodipine crystallized from the amorphous material under different conditions. It was 
found that when polymers are present during crystal evolution from an amorphous solid 
exposed to water, they can impact the size and shape of the resulting crystals. This in turn 
influences the subsequent rate of crystal growth from supersaturated solutions. Therefore, 
when testing the ability of polymers to impact crystal growth, and the impact of crystal 
seeds on the rate of desupersaturation, the crystallization conditions and treatment of the 
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seed crystals should be carefully considered in order to better evaluate the 
desupersaturation risk for supersaturating dosage forms.  
 
6.2 Introduction 
Control of crystallization from supersaturated solutions is essential in many 
industries. In the pharmaceutical field, crystallization control is important for 
manufacturing purposes, and as a means of enhancing drug delivery. The bioavailability 
of BCS Class II drug compounds is limited by their ability to dissolve to sufficiently high 
concentrations in the gastrointestinal tract,1 therefore these compounds are often 
formulated as amorphous solids in order to improve solubility.2,3 The higher free energy 
of the amorphous form compared to the crystalline form allows for increased dissolution 
rates and the generation of supersaturated solutions in vivo.4–6 Thus, this strategy has 
been found to increase drug absorption because supersaturated solutions can achieve 
superior membrane transport.7–9 However, rapid crystallization of these supersaturated 
solutions in vivo threatens the efficacy of this formulation strategy.10 Thus, the ability to 
inhibit crystal nucleation or growth to prolong supersaturation is desirable. 
 The ability of additives to modify crystal growth has been recognized for several 
decades.11,12 Additives can adsorb at active sites of growing crystals and impact growth 
either by altering the crystal’s interfacial energy,13 or by pinning growth steps, thus 
reducing the rate of step advancement.14 Polymers in particular have been successful at 
poisoning crystals, thereby reducing growth rates and stabilizing supersaturated solutions 
when added to the growth medium.15–17 Previous works have shown that their success 
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depends on their ability to adsorb to the crystal surface and achieve a high degree of 
surface coverage.18,19  
Additives such as polymers can also modify crystal morphology at the 
macroscopic scale.20–22 Adsorption of polymers and their subsequent effect on the 
advancement of steps of monomolecular height can impact the evolution of macrosteps, 
or terraces.21 Polymers have been shown to impede growth of specific crystal faces so 
that growth continues only in the direction of certain crystallographic planes, thus 
resulting in habit modification.20  
For amorphous formulations, crystal seeds may form during manufacturing or 
storage, or during the dissolution process. Therefore, there is interest in understanding 
how low levels of crystallinity can impact desupersaturation rates, and how polymers can 
retard this process. However, there is little understanding of how crystal seeds with 
different origins may impact the desupersaturation rate. It is likely that crystal seeds 
formed by crystallization of an amorphous drug will be different from material produced 
through conventional solvent crystallization, and that the presence of a polymer during 
the crystallization process (a polymer will be present in the majority of amorphous 
formulations) will further impact the seed characteristics. 
The goal of this work was to study polymer poisoning of crystal surfaces formed 
under different crystallization conditions and relate the changes in crystal morphology to 
variances in solution crystal growth rates. Polycrystalline surfaces of the active 
pharmaceutical ingredient (API) felodipine were grown from the amorphous melt in the 
absence and presence of the polymer HPMCAS. The crystalline surfaces were then 
exposed to supersaturated solutions of felodipine in the absence and presence of 
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HPMCAS and crystal growth rates were measured under carefully controlled 
hydrodynamic conditions. The surfaces were also characterized with atomic force 
microscopy (AFM). It was hypothesized that AFM characterization would reveal 
differences in crystal morphologies at the macroscopic scale as well as crystal growth 
mechanisms at the microscopic scale due to differences in how the polymer interacts with 
the drug at the molecular level. These variances were expected to impact crystal growth 
rates from supersaturated solutions.  
 
6.3 Experimental Section 
6.3.1 Materials 
The model poorly water-soluble API used in this study, felodipine, was purchased 
from Attix Pharmaceuticals (Toronto, Ontario, Canada). Methanol (HPLC grade), used to 
dissolve felodipine and create supersaturated solutions, was purchased from Avantor 
Performance Materials (Center Valley, PA). The polymer used in this study, 
hydroxypropylmethyl cellulose acetate succinate (HPMCAS) LF grade, Mw 18 000 g 
mol-1, was supplied by Shin-Etsu Chemical Co, Ltd. (Tokyo, Japan) in a powder form. 50 
mM pH 6.8 phosphate buffer with or without pre-dissolved HPMCAS was used as the 
medium for seed crystal growth from the amorphous melt, as well as for supersaturated 
solution crystal growth experiments. 50 mM pH 3 phosphate buffer was used as the 
medium for seed crystal growth from the amorphous solid dispersions. The molecular 
structures of felodipine and HPMCAS are given in Figure 2.5. 
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6.3.2 Seed Crystal Preparation 
Amorphous felodipine was prepared by melting the crystalline material from the 
supplier and pouring the melt onto AFM pucks (Ted Pella, Inc. Redding, CA), which sat 
inside custom-made cylindrical Teflon holders. The custom holders were necessary for 
crystal growth experiments using a rotating disk apparatus, explained further in Section 
6.3.3. Amorphous solid dispersions were made by grinding a 10% w/w mixture of 
HPMCAS powder and felodipine crystals using a mortar and pestle. The ground mixture 
was then melted and poured in the custom holders in the same manner as for the pure 
drug. Before the melts of pure drug or polymer/drug mixtures cooled, the surfaces were 
flattened using a glass coverslip, then allowed to cool before removal of the coverslip.  
 Polycrystalline surfaces were prepared from amorphous felodipine using four 
different methods. The methods, outlined below are also illustrated in Figure 6.1.  
i) Amorphous felodipine was exposed to aqueous phosphate buffer (pH 6.8) for up 
to 24 hours, allowing the surface to fully crystallize. 
ii) Amorphous felodipine was exposed to aqueous phosphate buffer (pH 6.8) for up 
to 24 hours, allowing the surface to fully crystallize. The crystalline surface was 
then exposed to buffer containing 5 µg/mL dissolved HPMCAS for three hours to 
allow maximum adsorption of the polymer onto the crystal surface, prior to 
commencing crystal growth rate experiments. 
iii) Amorphous felodipine was exposed to aqueous phosphate buffer (pH 6.8) 
containing 5 µg/mL dissolved HPMCAS for up to 24 hours, allowing the surface 
to fully crystallize. 
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iv) An amorphous solid dispersion of felodipine and HPMCAS was exposed to 
aqueous phosphate buffer (pH 3) for up to a week, allowing the surface to fully 
crystallize. 
These various preparation methods were chosen to explore the role of polymer in 
impacting the growth surface produced upon crystallization of the amorphous material. 
Method (i) serves as the control, method (ii) allows for evaluation of the impact of pre-
poisoning on the subsequent growth rate, while methods (iii) and (iv) enable assessment 
of the impact of having a polymer present when crystallization first occurs from the 
amorphous solid. Method (iv) represents the most likely scenario for an amorphous 
formulation, while methods (i) and (ii) more closely represents the type of approaches 
previously used to evaluate the impact of polymers on crystal growth. 
 
 
Figure 6.1. Illustrations depicting the different preparation methods of crystalline felodipine 
surfaces used in growth rate studies. The methods are described in Section 6.3.2. Beakers are 
color-coded to match the results presented in Section 6.4. Orange felodipine surfaces indicate that 
the surface was amorphous and the yellow surface indicates that the surface was crystalline. 
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6.3.3 Crystal Growth Rate Measurements 
Solution crystal growth rates of felodipine were measured in the absence and 
presence of dissolved HPMCAS. To generate supersaturated solutions, a small amount of 
a stock solution of 10 mg/mL solubilized felodipine in methanol was added to pH 6.8 
buffer alone, or buffer containing 5 µg/mL pre-dissolved HPMCAS or 100 µg/mL pre-
dissolved SDS. The equilibrium concentration, Ceq, of felodipine is approximately 0.5 
µg/mL at 25°C,15 and the generated bulk concentration, C, for growth experiments was 2 
µg/mL. Thus the experiments were performed at S = 4. 
Immediately after generation of supersaturated solutions, the polycrystalline 
surfaces prepared using the methods explained in Section 6.3.2 were exposed to the 
supersaturated solution. The concentration of felodipine as a function of time was 
measured to determine a desupersaturation profile, which is proportional to the growth 
rate. The custom-made Teflon holders containing the polycrystalline surfaces were 
mounted to a rotating disk apparatus (RDA) (Princeton Applied Research, Oakridge, TN. 
Model #616). The RDA was set to a constant rotational speed, 3000 rpm, at which there 
was no effect of the rate of solute mass transfer to the solid-liquid interface.23 Thus, the 
growth rates measured were determined purely by the rate of solute integration; the step 
impacted by polymer adsorption.  
Desupersaturation profiles were measured using a CCD Array UV-vis 
Spectrometer (SI Photonics, Tuscon, AZ). The intensity of an absorbance peak of 
felodipine (wavelength 238 nm) was recorded at 10-second intervals for 1 hour. All 
experiments were performed in triplicate. Calibration solutions, prepared in methanol, 
were used to correlate peak intensity to concentration. The slope of the resulting 
 104 
concentration v. time curve was recorded as the growth rate, R0 or RP, where R0 is the 
growth rate of felodipine crystals prepared with method (i) in supersaturated solutions 
containing no HPMCAS (i.e. the only growth experiment in which HPMCAS was not 
present in solution or on the seed crystals). RP represents the growth rate for all other 
experiments where HPMCAS is present on the seed crystals or dissolved in solution, or 
both. RP also represents the growth rate for experiments where SDS was dissolved in 
solution. The values of RP obtained were then compared to R0 by taking the ratio of the 
two.  
 !! = !!!!     (6.1) 
 
This gives the polymer effectiveness, Eg, in order to compare how effectively HPMCAS 
poisons felodipine crystal growth for each of the conditions studied. The larger the value 
of Eg, the more effectively HPMCAS has poisoned the surface and retarded crystal 
growth and hence the rate of desupersaturation.  
 
6.3.4 Surface Characterization with Atomic Force Microscopy 
Atomic force microscopy (Figure 2.3) (Multimode 8 AFM, Bruker Corporation, 
Technology Forest, TX) was used to characterize the crystalline surfaces following the 
growth experiments. Samples, which were already mounted on AFM pucks in the holder, 
were removed from the holder and immediately characterized in the same liquid used for 
growth experiments to ensure there was no surface dissolution. Characterization was 
performed using Tapping Mode. SNL-10 (0.24 N/m spring constant, 10 nm radius of 
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curvature) or NPG-10 (0.24 N/m spring constant, 30 nm radius of curvature) silicon 
nitride triangular probes (Bruker Corporation, Technology Forest, TX). Scan resolution 
was set to 512 x 512 pixels2 with scan rates of 0.4 – 0.5 Hz.  
Height images, amplitude images, and phase images were obtained 
simultaneously for each system. Height and amplitude both provide information on 
topographical changes of the surface. The amplitude is the raw feedback of tip deflection 
due to these changes; whereas height scans are the output of the tip deflection calibrated 
to a z-scale in order to generate 3D topographical images. Phase contrast imaging is 
sensitive to changes in material properties on the surface, thus it can be used to detect 
adsorbed polymers. 
Images were analyzed using NanoScope Analysis (v1.5, Bruker Corporation, 
Technology Forest, TX). Surface areas were determined using the software’s Roughness 
Analysis tool after images were normalized to a midline. Surface height features were 
measured using the software’s Cross Section tool.  
 
6.3.5 Contact Angle Measurements 
The contact angles of DI water and ethylene glycol on a crystalline felodipine 
surface grown from amorphous material in aqueous buffer were measured in order to 
determine the surface energy of crystalline felodipine. A Ramé-Hart model 500 
goniometer (Ramé-Hart Instrument co., Succasunna, NJ) and DROPimage advanced 
software were used. Ten contact angle measurements were taken for ten drops of each of 
the two liquids. From these results, an average contact angle for each of the two liquids 
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on felodipine was determined. The surface energy was then estimated using the harmonic 
mean approach proposed by Wu.24  
 
6.3.6 Determination of Felodipine Growth Unit Size 
The size of a felodipine growth unit was determined using the crystal structure 
visualization software, Mercury.25 The measure distances tool was used to measure the 
length and width of a felodipine molecule (form DONTIJ from the Cambridge 
Crystallographic Data Centre (CCDC) structural database). Using these measurements, 
the area occupied by a growth unit on a crystal surface was calculated. 
 
6.4 Results and Discussion 
6.4.1 Growth Rate Results 
Polycrystalline felodipine surfaces were exposed to supersaturated solutions of 
felodipine in the absence and presence of HPMCAS, and the crystal growth rate of 
felodipine was subsequently measured. The polycrystalline felodipine surfaces were 
prepared using four different methods (outlined in Section 6.3.2 and shown pictorially in 
Figure 6.1) in order to compare the impact of crystal preparation conditions on 
subsequent solution crystal growth rates, specifically the impact of having polymer 
present when the crystals first form from the amorphous material. Figure 6.2 shows the 
results of the growth rate studies, which are presented as the effectiveness ratio, R0/RP, 
defined in Section 6.3.3. Each of the four preparation methods is represented by a 
different color in Figure 6.2. The columns overlaid with a grid pattern represent growth 
 107 
rates measured in the presence of HPMCAS in solution, whereas the columns with no 
pattern have only felodipine in solution.  
 
 
Figure 6.2. Crystal growth rates of felodipine (S=4) presented as a ratio of the pure felodipine 
growth rate over the growth rate of crystals poisoned by HPMCAS (the effectiveness ratio). 
Gridded columns have 5 µg/mL HPMCAS present in solution during the growth rate 
measurements whereby samples were prepared using methods (i-iv). Non-gridded columns 
represent the same samples, which were crystallized using methods (i-iv), but where subsequent 
growth rate measurements were performed in a solution free of polymer. Experiments were 
performed in triplicate and each column represents the mean. Error bars indicate the standard 
deviation. 
 
The results in Figure 6.2 are presented in order of increasing effectiveness, Eg, 
which ranges from about 2 to 12. It is clear that crystal preparation method greatly 
impacted effectiveness. Additionally, whether or not HPMCAS was present in solution 
during growth also greatly impacted the resultant effectiveness factor. To understand 
mechanistically how crystal preparation environment produces these differences in 
polymer growth inhibition effectiveness, the systems were analyzed with atomic force 
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microscopy.  The growth rate results will be presented again in subgroups in order to 
focus on each preparation method separately.  
 
6.4.2 HPMCAS Pre-adsorbed on Seed Crystals 
Seed crystals were grown from amorphous felodipine immersed in liquid buffer, 
and then exposed to a solution containing dissolved HPMCAS for several hours (method 
ii). Thus, HPMCAS should have attained maximum surface coverage through adsorption 
to the crystal surface, before exposure to felodipine supersaturated solutions, which will 
drive new growth. Figure 6.3 compares the growth rate results for samples prepared with 
this method with the result for seed crystals grown in liquid with no HPMCAS pre-
adsorbed (method i). 
 
Figure 6.3. Effectiveness growth rate ratios for felodipine poisoned by HPMCAS. Effectiveness 
ratios of surfaces prepared using method (ii) are compared to method (i). Gridded columns have 5 
µg/mL HPMCAS present in solution during growth rate determination experiments. Experiments 
were performed in triplicate and each column represents the mean. Error bars indicate the 
standard deviation. 
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 The results indicate that when HPMCAS was pre-adsorbed on the crystalline 
felodipine surface and the growth rate was determined with HPMCAS in solution (red, 
gridded column), growth was considerably slower relative to the sample where HPMCAS 
was not pre-adsorbed and growth was measured with HPMCAS in solution (blue, gridded 
column). This result is anticipated since HPMCAS can attain greater surface coverage, 
and therefore more effectively pin growth steps when it has had time to reach a maximum 
surface coverage through the initial equilibration of the crystal surface with a solution 
containing polymer. However, when HPMCAS is not pre-adsorbed, it must compete with 
felodipine growth units for adsorption to active sites (blue, gridded column), and the 
polymer cannot block as many growth sites and therefore will not be as effective.  
The impact of first poisoning the surface by pre-adsorption of polymer, followed 
by growth experiments in a fresh solution containing no polymer was also examined. It is 
generally accepted that polymers adsorb irreversibly,26 therefore, the pre-adsorbed 
HPMCAS should remain adsorbed to the surface when exposed to fresh buffer, and 
would be expected to have some impact on growth rate.  Interestingly, when HPMCAS 
was pre-adsorbed and growth was measured with no HPMCAS in solution (red column 
on the left), the effectiveness was reduced compared to the sample prepared the same 
way, but with HPMCAS in solution during growth (red, gridded column). The growth 
rate was also more effectively reduced for a fresh crystal surface exposed to a 
supersaturated solution containing HPMCAS (blue, gridded column). This result 
indicates that the presence of HPMCAS in solution during the growth rate measurement 
is a key determinant of effectiveness, regardless of the pre-equilibration step.  
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AFM characterization of the crystalline surfaces after growth (Figure 6.4) 
provided insight into these results. Figure 6.4a is an image of a felodipine surface 
crystallized from the amorphous material from a solution free of polymer. The height 
features show monomolecular steps, which extend across the crystal face, providing 
evidence of step growth. 
 
Figure 6.4. 1 µm x 1 µm AFM amplitude images characterizing a single felodipine crystal face 
after one hour of growth from the supersaturated solution at initial S=4. (a) and (b) were prepared 
using method (i) and (c) and (d) were prepared using method (ii). Only (b) and (d) had HPMCAS 
(5µg/mL) present in the supersaturated solution during crystal growth. Images were captured in 
liquid at room temperature with an incubation time of about 3 h. 
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 Figure 6.4b shows the result of AFM characterization after the growth experiment 
in which HPMCAS was present in solution during growth rate measurements (there was 
no HPMCAS pre-adsorbed on the surface; this sample corresponds to the blue gridded 
column in Figure 6.3). The steps along the crystal face in Figure 6.4b look very different 
from those in Figure 6.4a. Instead of relatively even and linear steps across the face, the 
layers appear to be pinned at several points along each step, providing evidence of the 
pinning mechanism discussed in Section 1.5 and depicted in Figure 1.4. The result 
suggests that HPMCAS adsorbed at active growth sites along the steps and effectively 
pinned them, thereby slowing step advancement and increasing the step curvature. This 
explains the measured reduction in growth rate when HPMCAS was present in solution 
during the growth rate experiments. 
 Figure 6.4c shows the result of AFM surface characterization after growth of the 
felodipine crystal surface in a supersaturated solution which did not contain any polymer, 
whereby the initial crystal surface had pre-adsorbed HPMCAS (corresponding to the first 
red column in Figure 6.3). The surface appears very similar to that of felodipine 
crystallized completely in the absence of polymer (Figure 6.4a), and provides insight into 
why the effectiveness of this system is so low (Figure 6.3). Although HPMCAS was pre-
adsorbed onto the crystalline surface, felodipine growth was able to continue as if there 
was no polymer present on the surface. This suggests that when there is no polymer in the 
supersaturated solution competing for growth sites, a felodipine layer can grow over the 
adsorbed polymer molecules that are present on the crystal surface due to the pre-
adsorption step.  
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A second growth experiment, which was conducted immediately after the first 
growth experiment in a freshly supersaturated felodipine solution, confirmed that this is 
the case. The result, displayed in Figure 6.3 (second red column from the left) reveals an 
effectiveness ratio close to 1, that is, the pre-adsorbed polymer had no effect on the 
growth rate. It can therefore be concluded that during the first growth experiment, 
felodipine growth unit attachment was slowed slightly by the presence of the pre-
adsorbed polymer molecules, but nevertheless a pure drug layer was able to grow on top 
of the initially poisoned surface, creating a fresh surface for growth. Thus, in the second 
growth experiment, there was no inhibition of growth at all because the surface was 
essentially free of polymer. A similar result was observed in a study by Gratz and 
Hilner,22 in which re-growth was observed on poisoned crystals when introduced to a 
fresh supersaturated solution. This result points to the importance of having dissolved 
polymer present in solution during growth for effective inhibition. 
 Of all the growth rate results shown in Figure 6.3, the case where HPMCAS was 
present in the supersaturated solution during growth combined with pre-adsorption onto 
the surface (red, gridded column) achieved the greatest growth inhibition. Figure 6.4d 
reveals the AFM characterization of this sample after growth. The surface appears 
different from both of the previously discussed poisoned surfaces. Growth layers do not 
appear as steps traversing across the entire width of the face. Instead, they seem to 
originate from a point and grow outward in all directions, similar to the birth and spread 
mechanism (Figure 1.3b).11 Thus, when polymers are covering the surface prior to drug 
growth, and competing with drug growth units in solution for active sites, it appears that 
step pinning is so effective, it forces the entire step to curve rather than only forcing 
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localized curves along a linear step. This provides clear evidence that surface poisoning 
by polymers can change how the crystals evolve. 
 
6.4.3 Seed Crystals Grown in HPMCAS Solution 
The next logical step of investigation was to evaluate how polymers might disrupt 
the crystal surface during the initial crystallization from the amorphous material. Thus 
seed crystals were grown from amorphous felodipine in a solution containing dissolved 
polymers (method iii). The subsequent solution growth rate results for these crystals in 
the absence and presence of dissolved HPMCAS are presented in Figure 6.5. The growth 
rates of these surfaces are again compared to the growth rate of a surface crystallized 
initially in buffer and then further grown in the presence of HPMCAS (method i).  
 
Figure 6.5. Effectiveness growth rate ratios for felodipine poisoned by HPMCAS. Effectiveness 
ratios of surfaces prepared using method (iii, green columns) are compared to method (i, blue 
column). Gridded columns had 5 µg/mL HPMCAS present in solution during the growth rate 
measurements. Experiments were performed in triplicate and each column represents the mean. 
Error bars indicate the standard deviation. 
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The results in Figure 6.5 indicate that when seed crystals were initially formed in 
the presence of HPMCAS (gridded green column), the growth rate was considerably 
slower (higher effectiveness) than for seed crystals grown in pure buffer (gridded blue 
column), when HPMCAS was not present in solution during the growth rate 
determination. Just growing the crystals from the amorphous material in the presence of 
HPMCAS appeared to impact their ability to subsequently grow when exposed to a fresh 
supersaturated solution without polymer (green column). 
To understand the impact of HPMCAS on seed crystal growth from amorphous 
felodipine, the crystal surfaces were characterized with AFM. The resulting 3D 
topographical maps are shown in Figure 6.6, and they indicate that the presence of 
HPMCAS in the solution greatly impacts the size and shape of the resulting seed crystals 
that form from the amorphous drug. When grown in pure buffer solution (Figure 6.6a), 
the felodipine crystals had much larger macroscopic features than when they were grown 
in a solution containing HPMCAS (Figure 6.6b). This suggests that the HPMCAS in 
solution interfered with the growth mechanism, and impacted how the crystals evolved.  
 
Figure 6.6. 5 µm x 5 µm AFM 3D topographical maps of polycrystalline felodipine surfaces 
prepared using (a) method (i) and (b) method (iii). Images were captured in liquid at room 
temperature with an incubation time of 2-3 h. 
 115 
The morphology in Figure 6.6b could be the macroscopic effect of the growth 
pattern shown in Figure 6.4d. Since the crystals grew from amorphous felodipine in the 
presence of HPMCAS, which may have adsorbed to the surface prior to crystallization, it 
is likely that the polymer had an even more disruptive effect on crystal morphology, 
preventing the development of continuous, linear layer growth characteristic of the 
system crystallized in the absence of polymer, instead causing the growth of curved steps. 
Thus it is likely that the effect seen in Figure 6.4d is magnified in Figure 6.6b, whereby 
the crystallites were forced to grow vertically, similar to island growth, instead of 
horizontally as layers, as for the polymer-free crystalline surface. Consequently, the 
surface is composed of rough, spike-like features, rather than the large flat features seen 
in Figure 6.6a. 
The surface areas of both images were determined using roughness analysis 
(explained in Section 6.3.4), and the values are displayed in Table 6.1. It can be seen that 
despite the differences in morphology, the surfaces have very similar areas, therefore a 
surface area difference cannot explain the differences in the measured growth rates 
(Figure 6.5), as one might expect given their relationship (equation 1.5).  Instead, the 
growth rate differences must arise based on the relative availability of active growth sites 
for the different morphologies. The larger seed crystallites (Figure 6.6a), which grew at a 
faster rate from the supersaturated solution, have large faces, each of which contain many 
steps that extend across the face. The smaller crystallites (Figure 6.6b) cannot have such 




Table 6.1. Surface area values 





6.4.4 Seed Crystals Grown from Amorphous Solid Dispersions 
For amorphous solid dispersion (ASD) formulations, crystals will most likely 
evolve from the ASD during production, storage or the hydration step of the dissolution 
process, and it is of interest to determine the extent to which crystals evolved from this 
environment can lead to desupersaturation. Thus, seed crystals were grown from 
amorphous solid dispersions containing felodipine and HPMCAS (method iv). When the 
crystallized ASD was exposed to supersaturated solutions of felodipine, the resulting 
growth rate inhibition (yellow columns) was even greater than for the previously 
discussed case of seed crystals grown from a pure felodipine melt in the presence of 
HPMCAS (green columns). This is displayed in Figure 6.7. For the case where HPMCAS 
was present in solution during growth (yellow, gridded column), the effectiveness ratio is 
12, indicating a very significant reduction in growth rate due to highly effective surface 




Figure 6.7. Effectiveness growth rate ratios for felodipine poisoned by HPMCAS. Effectiveness 
ratios of surfaces prepared using method (iv) are compared to method (iii). Gridded columns have 
5 µg/mL HPMCAS present in solution during growth. Experiments were performed in triplicate 
and each column represents the mean. Error bars indicate the standard deviation. 
 
 Such effective surface poisoning is likely due to the fact that an ASD is an 
intimate mixture of API and polymer. In previous studies that have assessed the ability of 
polymers to stabilize ASDs, it was found that the more effective stabilizers could form 
strong specific interactions with the API.27,28 These interactions between polymer and 
drug can disrupt crystal evolution more effectively than any of the methods previously 
discussed where the polymer is only present in the solution phase, and not mixed with the 
amorphous drug. Based on the results presented in Section 6.4.3, it was hypothesized that 
the surface features of seed crystals grown from an ASD would be even smaller than the 
features of seed crystals grown in polymer solution (method iii). 
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Figure 6.8. 1 µm x 1 µm AFM 3D height images of polycrystalline felodipine surfaces prepared 
using (a) method (iii) and (b) method (iv). Images were captured in liquid at room temperature 
with an incubation time of 2-3 h. 
 
 AFM height characterization (Figure 6.8) confirmed this hypothesis. Seed crystals 
grown from the ASD (Figure 6.8b) had much smaller features than seed crystals grown 
from a felodipine melt in HPMCAS solution (Figure 6.8a). (Note that the scan area of 
Figure 6.8 is smaller than that of Figure 6.6). The very small features in Figure 6.8b 
appear to be a result of the pinning mechanism. Cross-sectional analysis was performed 
to determine if the features were monomolecular in height. Two examples of the results 
obtained from the analysis are shown in Figure 6.9. Table 6.2 displays the average value 
of the step height, h, determined from the analysis along with the average value of h for 
the pinned steps of the system shown in Figure 6.4b for comparison. The analysis 
indicates that the average height features of these systems are similar and are both 
comparable to the molecular length of felodipine, which is about 0.8 nm. Thus, it was 




Figure 6.9. AFM cross-sectional height analysis of steps on a crystalline surface grown from an 
ASD of felodipine and HPMCAS. 
 
Table 6.2. Values of h and l determined from AFM cross-sectional analysis. 
Figure h (nm) l (nm) 
6.8b 0.77 ± 0.2 15.8 ± 7.4 
6.4b 0.81 ± 0.2 68.5 ± 9.4 
 
According to the Kubota-Mullin model, which describes growth inhibition by 
adsorbed impurities such as polymers, a smaller radius of curvature, ρ, of a pinned step 
results in better growth inhibition, and ρ = l/2, where l is the average distance between 
adsorbed polymers.  If l ≤ ρc (the critical nucleus radius) then step advancement will stop 
(equation 1.12).14 Thus, values of l were determined by measuring the step radii using 
cross-sectional analysis. The results for both the crystals grown from the ASD, and for 
the pinned steps shown in Figure 6.4b are presented in Table 6.2.  
The average distance between adsorbed polymers for the surface grown from the 
ASD was more than four times smaller than that of the pinned steps in Figure 6.4b (the 
result of growth in the presence of HPMCAS on a crystalline face grown from pure 
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amorphous felodipine exposed to just buffer). The critical nucleus radius, ρc, was 
calculated using equation (1.6) in order to compare its value to these measured values of l. 
The quantities used in equation (1.6) are listed in Table 6.3, and explanations for how 
values of γ and a were obtained are given in Sections 6.3.5 and 6.3.6.  
 
Table 6.3. Values used to calculate ρc (equation 1.6) 
Parameter Value ! 3.9x10-20 J/nm 
a 0.584 nm2 
k 1.38x10-23 J/K 
T 298.15 K 
lnS 1.39 
 
The critical nucleus radius for felodipine at the current experimental conditions 
was determined to be ρc = 3.98 nm. Comparing this to the measured values of l 
(displayed in Table 6.2), ρc is smaller than both values, explaining why felodipine growth 
was not stopped completely in either case. However, the value of l for the ASD is much 
closer to ρc, providing quantitative validation for why the effectiveness ratio of the ASD 
was about three times greater in the absence of HPMCAS (yellow column compared to 
blue gridded column in Figure 6.2), and nearly five times greater in the presence of 
HPMCAS (yellow gridded column compared to the blue gridded column in Figure 6.2).  
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6.4.5 Impact of Growth Environment 
Thus far, the impact of the environment during crystallization of amorphous 
felodipine has been shown to be of great importance to the morphology of the resultant 
crystalline surface, with surface poisoning effects by HPMCAS being readily apparent. 
This in turn impacts how quickly the crystals can grow in a supersaturated solution. The 
other important factor highlighted in the results so far is the presence of dissolved 
HPMCAS in solution, which competes with felodipine growth units for active growth 
sites on the surface, reducing the rate of crystal growth. The results indicated that when 
HPMCAS was present in the growth medium, it could continue to effectively poison the 
surface and dictate how the crystals evolved. However, for the cases where HPMCAS 
was incorporated onto the crystal surface, but was not present in the growth medium, 
felodipine could deposit as fresh layers on top of the poisoned surface and the impact of 
surface poisoning by the polymer was reduced. This highlights the importance of the 
solution growth environment.  
To further probe the importance of growth environment, felodipine crystal growth 
rates (of seed crystals prepared using method i) were measured in the presence of the 
surfactant, SDS. Surfactants are frequently present in solution both during in vitro testing 
of amorphous formulations and in vivo, and may even be added to the formulation The 
results are presented in Figure 6.10 along with the result for growth in the presence of 




Figure 6.10. Effectiveness growth rate ratios for felodipine in the presence of SDS (100 µg/mL) 
and/or HPMCAS (5µg/mL). Felodipine surfaces for all experiments were prepared using method 
(i). Gridded columns have HPMCAS present in solution during growth. Experiments were 
performed in triplicate and each column represents the mean. Error bars indicate the standard 
deviation. 
 
For the case where SDS and HPMCAS were both present in solution, crystal 
growth was faster than for the case of HPMCAS alone. It was hypothesized that this 
could be due to the possibility that SDS prevents HPMCAS from adsorbing on the 
surface via steric hindrance by adsorbed SDS molecules. However, AFM phase 
characterization, which is sensitive to surface material properties, provided evidence that 
this was not the case. Figure 6.11 shows AFM phase contrast imaging of a pure 
felodipine surface (Figure 6.11a), a felodipine surface after exposure to HPMCAS 
(Figure 6.11b), and a felodipine surface after exposure to a mixture of HPMCAS and 
SDS (Figure 6.11c). It can be seen that Figures 6.11b and 6.11c look similar, wherein 
both exhibit dark shading indicative of adsorbed HPMCAS. By comparison, the pure 
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drug surface does not have this dark shading. If SDS prevented the adsorption of 
HPMCAS, Figure 6.11c would be expected to look similar to Figure 6.11a. 
 
 
Figure 6.11. 1µm x 1µm AFM phase images of (a) a pure felodipine crystal face, (b) a felodipine 
crystal face after exposure to HPMCAS (5 µg/mL), and (c) a felodipine crystal face after 
exposure to a mixture of HPMCAS (5 µg/mL) and SDS (100 µg/mL). Images were captured in 
liquid at room temperature with an incubation time of 2-3 h. 
 
 A possible explanation for the increase in growth rate in the presence of SDS 
could be a change in the interfacial energy of felodipine in contact with water due to the 
adsorbed surfactant. Thus, the growth rate of felodipine was measured in the presence of 
SDS only. It can be seen in Figure 6.10 that the effectiveness ratio, R0/RP < 1, indicating 
that the growth rate when SDS was present was actually faster than the growth rate of the 
pure drug. A similar result was observed by Chen et al. where some surfactants were 
shown to accelerate crystallization.29 This result can be explained by a reduction in the 
interfacial energy, γ, by the surfactant, thereby decreasing the critical nucleus radius 
(equation 1.6).  
This result highlights the importance of the crystallization medium. Drug 
formulations include several excipients, and often surfactants are used as solubilizing 
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agents.30 If a formulation includes a combination of polymer and a surfactant such as 
SDS, this could potentially negatively impact stabilization of the supersaturated solution 
once the drug has dissolved in vivo, and thereby decrease drug absorption. 
 
6.5 Conclusions 
The ability of the polymer HPMCAS to poison felodipine crystals was assessed. 
Polycrystalline felodipine surfaces were prepared from amorphous material using four 
different methods involving exposure to aqueous solutions with and without HPMCAS 
and it was found that the solution growth rates of the resultant crystals varied greatly. 
Characterization of the surfaces with atomic force microscopy revealed discernible 
differences in the morphology of the surfaces as well as the growth mechanisms. It was 
concluded that surface poisoning by polymers can have a large impact on crystal 
morphology and consequently, crystal growth rates.  
In addition, it was found that the presence of HPMCAS in solution during growth 
reduced growth rates, regardless of the surface preparation method. AFM characterization 
revealed that when crystals were grown in solution in the absence of HPMCAS, fresh 
layers of drug were able to grow on top of the poisoned surface. When HPMCAS was 
present in solution during crystal growth, evidence of step pinning was observed, 
explaining the reduced crystal growth rates. This study highlights that seed crystals 
prepared in different environments have different abilities to subsequently grow, a factor 
that should be considered when evaluating polymers as growth rate inhibitors, and 
evaluating the risk of desupersaturation from amorphous formulations containing residual 
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crystals. The insights gained from this study can be used to control crystallization and 
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CHAPTER 7. CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
WORK 
In the work presented in the preceding chapters of this dissertation, the impact 
of adsorbed polymers on crystal growth inhibition was studied. Several important 
conclusions were made from the results of this work. It was found that crystal growth 
in the presence of polymers impacted the kinetics of solute integration onto the 
crystal lattice. Another conclusion was that adsorbed polymer conformation greatly 
impacted the effectiveness of polymers as crystal growth inhibitors. The adsorbed 
conformation was affected by certain polymer properties such as ionization state and 
hydrophobicity. Finally, it was found that polymers impacted crystal morphology and 
crystal growth mechanism. These conclusions and the results that led to them open up 
many new questions and possibilities for future studies.   
In Chapter 3, the kinetics of felodipine crystallization was impacted by the 
presence of HPMCAS. Specifically, the kinetic constants for the integration steps, kr 
and r were shown to change. It was speculated that the change in r, the integration 
order, could be due to change in growth mechanism when polymers are present. The 
work of Chapter 6 provided evidence that the presence of polymers can indeed 
change growth mechanism. However, a definite link between integration order and 
growth mechanism has not yet been made. Therefore, it is recommended that the 
integration kinetics for systems with different growth mechanisms be studied in order 






The work presented in Chapters 4 and 5 showed that polymers that adsorbed 
in a coiled globule formation had reduced inhibitory impact compared to polymers 
that adsorbed in an extended chain conformation. This is because the globule 
formation leaves many growth sites open and available on the crystal for drug growth 
units to adsorb. In contrast, more growth sites are blocked when the polymer is more 
evenly distributed on the surface. Accordingly, in Chapter 5, polymer fractional 
surface coverage was shown to correlate linearly to polymer effectiveness. 
This work served as a proof-of-concept for this correlation between surface 
coverage and polymer effectiveness. The ultimate goal is that the correlation can be 
used to aid in polymer selection during drug product formulation. However, it is not 
practical for pharmaceutical companies to measure the surface coverage for every 
drug-polymer combination in order to predict effectiveness.  
Therefore, it is recommended that this work be expanded upon to include 
other active pharmaceutical ingredients (API) and an even broader range of polymers. 
If other APIs with properties similar to felodipine are found to exhibit a very similar 
correlation when studied with the same group of polymers, then that correlation 
would be proven to be predictive for new drug compounds with properties similar to 
felodipine.  
Next, another set of model compounds that exhibit different properties from 
the set already studied could be assessed in order to build up a model correlation to 
describe polymer effectiveness for new drugs similar to that set. Expanding the study 







Another finding of the work in Chapter 4 was that HPMCAS adsorption was 
shown to adsorb to multiple crystal faces with various surface chemistries. Thus, it 
was concluded that HPMCAS adsorption was non-specific. It is possible that this 
non-specificity is due to the fact that HPMCAS has both hydrophilic and hydrophobic 
groups. For the polymers, such as PVP that are very hydrophilic, or PVAc that are 
very hydrophobic, it is still unclear whether these polymers will selectively adsorb to 
faces that exhibit properties similar to their own.  
Therefore, another recommendation for future work is to study polymer 
adsorption onto amorphous drug surfaces. Using these surfaces, it is possible to 
control for surface chemistry because it is homogeneous. It is hypothesized that 
hydrophobic polymers would be more likely to adsorb to the more hydrophobic APIs 
and vice versa. This study would provide valuable insight into polymer adsorption 
specificity. 
In Chapter 6, it was concluded that growth environment greatly impacted 
crystal growth rates. When poisoned crystalline surfaces of felodipine were exposed 
to supersaturated solutions containing HPMCAS, the growth rates were consistently 
slower than when they were exposed to solutions with no HPMCAS. Furthermore, 
when SDS was present in solution during growth, felodipine growth rates increased 
compared to the pure system.  
Therefore, it is recommended that the impact of growth environment be 
explored further. In particular, it would be interesting to simulate the conditions of the 






determine if other components present in the digestive system such as bile salts have 
an impact on polymer adsorption or conformation.  
Finally, in the work presented in this dissertation, properties such as polymer 
concentration as well as API supersaturation remained constant within each study in 
order to keep the experiments controlled. The exception to this was the study in 
Chapter 5, in which PVPVA adsorption was studied at a higher polymer 
concentration. It was found that doubling the polymer concentration increased 
polymer surface coverage, but not by a factor of two. PVPVA adsorbed in the globule 
conformation at both the lower and higher concentrations, and the higher 
concentration increased the number of globules, but not the size of them. The latter is 
certainly a possibility, as is the suggestion that polymer concentration could change 
the adsorbed conformation altogether. Therefore it would be interesting to study the 
impact of polymer concentration on adsorbed conformation. The evidence from one 
system is not enough to draw any certain conclusions. Furthermore, it would be 
interesting to study the impact of API concentration on polymer conformation. These 
suggestions for future studies would greatly enhance our understanding of the impact 











Appendix A. ASSESSING THE STABILIZATION POTENTIAL OF VARIOUS 
POLYMERS FOR SPRAY-DRIED AMORPHOUS LACTOSE 
This appendix is a preprint with minor modifications of a manuscript submitted with the 
same title by: Caitlin J. Schram, Tony Howes, and Stephen P. Beaudoin. It describes 




A large proportion of pharmaceutical compounds have poor aqueous solubility, 
hindering their bioavailability. Formulating these compounds as amorphous solids, using 
methods such as spray drying, can improve their solubility and enhance delivery. 
Additives, such as polymers, are often utilized to stabilize amorphous solids, therefore it 
is necessary to evaluate how they can influence crystallization behavior. In this study, the 
stabilization potential of five different polymers was assessed, with the goal of examining 
the impact of both functional group chemistry and backbone structure. It was found that 




! More than 75% of active pharmaceutical ingredients (API) currently under 
development have poor aqueous solubility1. This poses a problem for oral therapeutics 
due to decreased bioavailability2. Utilizing the amorphous form of the drug, which has a 
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higher overall free energy than the crystalline form, is an effective method to alleviate 
solubility issues and therefore improve drug delivery3,4.  
Recent literature has described methods that attempt to stabilize the inherently 
unstable amorphous form and prevent crystallization2. One such method is the addition of 
polymers to the system. The ability of polymers to stabilize an amorphous API has been 
attributed to several factors including decreased molecular mobility and the formation of 
specific drug-polymer interactions5–7. Thus, the formation of a solid drug-polymer 
dispersion, in which the API is dispersed as an amorphous material within a polymeric 
matrix, is reported as an effective means of inhibiting crystallization8–10. Amorphous 
solid dispersions can be prepared in a number of ways8. Spray drying is one such method 
that has proven to produce amorphous material due to rapid conversion of a liquid 
solution to a dry powder by evaporation11. 
Although not an API, lactose is chosen as the model for this study due to its well-
documented crystallization properties12–15 as well as its wide use as an excipient in solid 
dosage forms16.  Due to its thermodynamic instability, amorphous lactose will crystallize 
over time when exposed to a humid environment. Amorphous lactose is extremely 
hygroscopic. Its molecules are configured such that hydrogen bonding sites are 
exposed13. As these sites bind to the water molecules in the air, the water content in the 
solid increases and the glass transition temperature (Tg) of the solid decreases. When the 
Tg drops below the experimental temperature, the lactose will crystallize17. In other 
words, exposure to humid air lowers the activation energy barrier towards 
crystallization12. Thus, the extent of lactose crystallization increases with increasing RH 
and time13.  
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In this study, α-lactose monohydrate was spray dried with a number of polymers 
and exposed to humid air in order to assess the effectiveness of each polymer at 
inhibiting lactose crystallization. Previous studies have indicated that the polymers that 
form stronger hydrogen bonds with the compound can more effectively stabilize an 
amorphous system18–20. Other studies have suggested that polymers that can decrease the 
molecular mobility of the compound by increasing its Tg will be effective21. Each of the 
polymers used in this study were selected solely based on their structure, with the 
intention of examining the effect of functional groups and backbone structure on a 
polymer’s ability to interact with lactose and inhibit crystallization.  
 
A.3 Materials and methods 
A.3.1 Materials 
 α-lactose monohydrate (Mw 360.31 g mol-1), Poly(vinylpyrrolidone) (PVP, Mw 
40,000 g mol-1), and polyacrylonitrile (PAN, Mw 150,000 g mol-1) were purchased from 
Sigma-Aldrich (Sydney, Australia). Poly(acrylic acid) (PAA, Mv ~450,000 g mol-1), 
Poly(ethylene succinate) (PES, ave Mw 10,000 g mol-1), and Poly(trimellitic anhydride 
chloride-co-4,4’-methylenedianiline) (PTM, Mw not given) were purchased from Sigma-
Aldrich (St Louis, MO, USA). Figure A.1 shows the molecular structures of the polymers 
and lactose. Saturated salt solutions of K2CO3 and NaCl were used to generate air of 44 




Figure A.1. Chemical structures of (a) α-lactose monohydrate, (b) PES, (c) PAA, (d) PVP, (e) 




A.3.2 Spray Drying 
 Pure α-lactose monohydrate or a mixture of lactose and 20% (w/w) polymer was 
added to DI water to give a solution containing 20g solid/100mL solution. The solutions 
were spray dried using a Buchi B-290 Mini Spray Dryer (Buchi Labortechnik AG, 
Switzerland). The process conditions, given in Table A.1, were constant for all 
experiments, except for the lactose/PAA composite, which was spray-dried at a lower 
inlet temperature due to the low decomposition temperature of PAA. To ensure rapid 
drying of this sample at the lower inlet T, the feed rate was also lowered. The spray-dried 
powders were stored in a desiccator for 24 hours before being moved to RH chambers 




Table A.1. Spray drying process conditions 
Parameters Settings 
Feed flow (ml/min) 8.5 
Inlet temperature (°C) 185 




A.3.3 Assessment of crystallinity 
 X-ray diffraction (XRD) patterns were obtained using a D8 Advance X-ray 
Powder Diffractometer (Bruker Corporation, Billerica, MA), to assess the crystalline 
content of each sample before and after storage at 44% and 75% RH. Samples were also 
assessed using a differential scanning calorimeter (DSC) (Q10, TA instruments, New 
Castle, DE, USA, aluminium non-hermetically sealed pans, calibration with indium). 
Samples were heated from 30°C to 260°C at a rate of 10°C/min. DSC has been shown to 
be a suitable semiquantitative method to determine the crystallinity of lactose22. XRD and 
DSC were performed on the pure spray dried lactose sample and each of the 7 spray dried 






A.4 Results and discussion 
A.4.1 Properties of spray-dried powders before storage 
X-ray diffraction patterns for spray-dried lactose and composite particles before 
storage are shown in Figure A.2. Each pattern shows broad and diffuse maxima, 
indicating that all spray-dried samples were amorphous.  
 
Figure A.2. XRD patterns of spray-dried lactose and lactose/polymer composites before storage 
 
 
DSC thermograms of the spray-dried materials before storage are shown in 
comparison to α-lactose monohydrate in Figure A.3. The thermogram of crystalline α-
lactose monohydrate exhibits a broad endothermic peak at ~150 °C, signifying 
dehydration of crystalline water12,22. In contrast, pure spray dried lactose shows an 
exothermic reaction at ~103 °C, signifying the crystallization event12,22. The five spray-
dried composites also exhibit the exothermic peak typical of an amorphous material, 
however this peak is shifted to a higher temperature for each of the composites (up to 
~130 °C), indicating that the incorporation of polymers requires more energy for 
 139 
crystallization to occur. This has been observed in previous studies of spray-dried 
lactose/PVP composites23.  
 
Figure A.3. DSC thermograms of spray-dried lactose and lactose/polymer composites before 
storage. 
 
Spray drying and recrystallization of lactose can result in mutarotation of α-
lactose to β-lactose13. The two forms differ in the orientation of a hydroxyl group on the 
glucose unit24. The mechanism of mutarotation occurs via an intermediate aldehyde form. 
This mechanism can be modelled as a first order reaction in which proton transfer, 
assisted by a water molecule, and the opening of the pyranosidic ring occur 
simultaneously25.  
It can be seen from Figure A.3 that both α-lactose monohydrate and pure spray-
dried lactose exhibit an endothermic heat of fusion peak at ~222 °C, indicative of the 
alpha form. Spray-dried lactose also shows a very small β peak at 230°C, demonstrating 
that a small amount of mutarotation has occurred upon crystallization. This is as expected 
since lactose is dissolved in aqueous solution before spray drying, and the two isomeric 
forms are both present in aqueous solution in a reversible equilibrium24. The spray-dried 
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composites each exhibit a different ratio of the α and β forms upon re-crystallization 
compared to pure spray-dried lactose. The effect of polymers on mutarotation will be 
discussed further in Sections A.4.3 and A.4.4. 
 
A.4.2 Impact of Polymers on Lactose Crystallization 
In order to assess the stabilizing effect of polymeric additives on lactose 
crystallization, each of the spray-dried samples were exposed to air of 44% and 75% 
relative humidity for three days. The critical RH for lactose crystallization has been 
reported as between 43 and 45% RH26. The XRD patterns for each sample are shown in 
Figure A.4. The patterns are displayed with the diffractogram of a-lactose monohydrate 
for comparison. The diffractograms show that all samples possess some degree of 
crystallinity, and that as expected, the samples exposed to 75% RH have higher and 
sharper peaks, and therefore possess a higher degree of crystallinity than the samples 
exposed to 44% RH due to the increased crystallization driving force at the higher 






Figure A.4. X-ray diffraction patterns after storage at 44% (red) and 75% (green) relative 
humidity of spray-dried (a) pure lactose, and spray-dried composites containing (b) PES, (c) 
PAA, (d) PVP, (e) PTM, and (f) PAN. Diffractograms are compared to crystalline α-lactose 
monohydrate (black).  
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The percent of lactose crystallized at 75% RH for each sample (calculated relative 
to α-lactose monohydrate) are displayed in Table A.2. It can be seen that the composite 
spray-dried with PAA has the lowest percent crystallinity, indicating that PAA is the 
most effective crystallization inhibitor. For the samples exposed to 75% RH, the order of 
effective inhibitors is: PAA > PVP > PES > PAN > PTM. 
 
Table A.2. Calculated % Crystallinity of lactose 
Sample % Crystallinity 
Pure lactose 55.5 
PES composite 50.6 
PAA composite 39.8 
PVP composite 45.5 
PTM composite 53.8 
PAN composite 51.9 
 
 
All freshly spray-dried composites were also stored for 10 days at 75% RH. These 
samples along with the samples stored at 44% and 75% RH for 3 days were characterized 
with DSC, and the results are shown in Figure A.5. It can be seen that the thermograms 
for samples stored at 75% RH for 10 days compared to 75% RH for 3 days look very 
similar for all samples. This implies that there were not many changes in stability during 







Figure A.5. DSC thermograms of spray-dried (a) pure lactose, and spray-dried composites 
containing (b) PES, (c) PAA, (d) PVP, (e) PTM, and (f) PAN. Characterization was performed 
before storage (black) and after storage at 44% RH for 3 days (red), at 75% RH for 3 days (blue), 




The DSC thermograms of pure lactose after storage (Figure A.5a) exhibit 
dehydration peaks around 150°C, which increase in magnitude as RH increases, as 
expected due to higher % crystallinity. The dual dehydration peaks indicate the presence 
of two types of hydrates17. Composites with PTM and PAN (Figures A.5e and A.5f) have 
similar DSC thermograms compared to the pure lactose samples at all three storage 
conditions. This is not surprising given that the XRD results indicate that these two 
polymers had little effect on lactose crystallization. The DSC thermograms of PAA and 
PVP composites (Figures A.5c and A.5d) stored at 44% RH for 3 days both exhibit an 
exothermic peak indicative of amorphous material, similar to the spray-dried sample 
before storage. These results agree with the XRD results, which indicated that PVP and 
PAA were the most effective stabilizers.  
 
A.4.3 Assessment of Lactose Mutarotation 
The XRD diffractograms of recrystallized pure lactose (Figure A.5a) show peaks 
at 10.5° and 21°, both of which are not present in the α-lactose monohydrate spectrum. 
Peaks at these two diffraction angles are characteristic of the β form27. Therefore, it is 
evident that mutarotation occurs upon recrystallization of spray-dried lactose, in 
agreement with the DSC results discussed in Section A.4.1. Previous studies have shown 
a similar result13 and it could be due to high spray-drying temperatures. Similarly, the 
XRD patterns of lactose spray dried with PES (Figure A.4b), PTM (Figure A.4e), and 
PAN (Figure A.4f), also show evidence of mutarotation for both storage conditions. 
Interestingly, lactose spray-dried with PAA (Figure A.4c) does not mutarotate to the β 
form upon recrystallization, and lactose spray-dried with PVP (Figure A.4d) is only 
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present in the β form when exposed to 75% RH. The DSC thermograms of the samples 
(Figure A.5) after storage show similar results, whereby the β form (endothermic peak at 
~240°C) dominates for all stored samples, except PAA composites, and PVP composites 
stored at 44% RH. 
These results suggest that mutarotation is linked to stability. PAA was determined 
to be the best stabilizer, and there is no evidence of transformation to the β form for 
lactose spray-dried with PAA. PVP was the second best stabilizer and composites with 
PVP remained in the α form at the lower relative humidity. All other samples, which 
were not stabilized as effectively by the polymers, transformed to the β form upon 
crystallization. This will be explored further in Section A.4.4. 
 
A.4.4 Assessment of polymer structure on stabilization  
 The ranking for crystallization inhibition was: PAA > PVP > PES > PAN > PTM. 
Comparing this order to the polymer molecular structures shown in Figure A.1, it is clear 
that there is no significant effect of polymer backbone structure on stability. PTM was the 
polymer studied which did not have a chain backbone. It was hypothesized that its ring-
structured backbone could increase its stabilization potential because it could more 
effectively hinder the mobility of lactose molecules, slowing their arrangement into a 
lattice structure. Because of its larger backbone structure, PTM also had the highest Tg. It 
was thought that this should increase the Tg of the lactose composite and therefore slow 
crystallization. However, since it was the least effective stabilizer, the results indicated 
that functional group chemistry, not backbone structure or Tg, is the most important 
factor. 
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 PAA and PVP were the most effective crystallization inhibitors. Both polymers 
contain a C=O group, which is a strong hydrogen bond acceptor. Trasi et al. have shown 
evidence using FTIR of hydrogen bonding between the carbonyl groups of PAA and PVP 
and the –OH group of acetaminophen19. It can be seen from Figure 1 that lactose contains 
numerous –OH groups, a strong hydrogen bond donor group. As stated in Section A.2, 
crystallization of lactose in humidity occurs via binding of water to the exposed –OH 
groups13. Thus, it can be concluded that PAA and PVP are able to hydrogen bond 
strongly to these groups, inhibit the interactions between lactose and water, and therefore 
slow crystallization. This conclusion aligns with the mutarotation results discussed in 
Section A.4.3. Water molecules assist the proton transfer step during mutarotation25. 
Since polymers that are able to form strong hydrogen bonds with lactose are inhibiting 




 The ability of five different polymers to stabilize spray-dried amorphous lactose 
was assessed. It was found that PAA and PVP were the best crystallization inhibitors. 
The results suggest that polymer functional group chemistry is more important than 
polymer backbone structure for crystallization inhibition.  PAA and PVP both have 
strong hydrogen bond acceptor groups, thus they are able to interact strongly with lactose 
and inhibit the interaction of lactose with water. This allows the polymers to stabilize the 
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Appendix B. SUPPORTING DATA 
 
This appendix shows the desupersaturation profiles measured using UV-vis spectrometry. 
The slopes of these profiles were used to generate the data points of the growth rate 
figures presented in this dissertation. Each data point is the average of three profiles, each 
multiplied by the volume of the solution. The raw data filenames are given for the UV 


























Figure B.1. (a-c) Desupersaturation profiles for pure felodipine (S of 4, no polymers 













Figure B.2. (a-c) Desupersaturation profiles for pure felodipine (S of 4, no polymers 













Figure B.3. (a-c) Desupersaturation profiles for pure felodipine (S of 4, no polymers 














Figure B.4. (a-c) Desupersaturation profiles for pure felodipine (S of 4, no polymers 














Figure B.5. (a-c) Desupersaturation profiles for pure felodipine (S of 4, no polymers 















Figure B.6. (a-c) Desupersaturation profiles for pure felodipine (S of 4, no polymers 













Figure B.7. (a-c) Desupersaturation profiles for pure felodipine (S of 4, no polymers 















Figure B.8 (a-c) Desupersaturation profiles for pure felodipine (S of 4, no polymers 














Figure B.9. (a-c) Desupersaturation profiles for pure felodipine (S of 4, no polymers 














Figure B.10. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 














Figure B.11. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 














Figure B.12. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 














Figure B.13. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 












Figure B.14. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 












Figure B.15. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 














Figure B.16. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 















Figure B.17. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 













c) 04072014_RDAexp_6000rpm_Sof4_wHPMCAS_2 and 
04072014_RDAexp_6000rpm_Sof4_wHPMCAS_2(2) 
 
Figure B.18. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 




























































B.3 Data for Figure 4.2 
a) From RS data  
 
b) From RS data  
 
c) From RS data  
 
Figure B.23. (a-c) Desupersaturation profiles for felodipine (S of 8, no polymers present) 








a) From RS data  
 
b) From RS data  
 
c) From RS data  
 
Figure B.24. (a-c) Desupersaturation profiles for felodipine (S of 8) with 5 µg/mL 









a) From RS data  
 
b) From RS data  
 
c) From RS data  
 
Figure B.25. (a-c) Desupersaturation profiles for felodipine (S of 8) with 5 µg/mL 














c) 03312015_RDAexp_6000rpm_Sof4_wPAA and 
03312015_RDAexp_6000rpm_Sof4_wPAA(2) 
 
Figure B.26. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL PAA 













Figure B.27. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL PVP 
















Figure B.28. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 















Figure B.29. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 














Figure B.30. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL P2VP 
















Figure B.31. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL PVAc 













Figure B.32. (a-c) Desupersaturation profiles for felodipine (S of 4) with 10 µg/mL 














Figure B.33. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL PVP 












c) 03102015_RDAexp_6000rpm_Sof4_wPVPandPVAc_10ug and 
03102015_RDAexp_6000rpm_Sof4_wPVPandPVAc_10ug_2 
 
Figure B.34. (a-c) Desupersaturation profiles for felodipine (S of 4) with 10 µg/mL PVP 














Figure B.35. (a-c) Desupersaturation profiles for felodipine (S of 4) prepared using 












Figure B.36. (a-c) Desupersaturation profiles for felodipine (S of 4) prepared using 
method (ii). Growth was measured with no polymer present, 2nd growth experiment. ω 












Figure B.37. (a-c) Desupersaturation profiles for felodipine (S of 4) prepared using 













Figure B.38. (a-c) Desupersaturation profiles for felodipine (S of 4) prepared using 













Figure B.39. (a-c) Desupersaturation profiles for felodipine (S of 4) prepared using 













Figure B.40. (a-c) Desupersaturation profiles for felodipine (S of 4) prepared using 












Figure B.41. (a-c) Desupersaturation profiles for felodipine (S of 4) prepared using 














Figure B.42. (a-c) Desupersaturation profiles for felodipine (S of 4) with 5 µg/mL 












Figure B.43. (a-c) Desupersaturation profiles for felodipine (S of 4) with 100 µg/mL 






B.8 AFM and IR-AFM Data 















5.2a cjs_20150506_SNL_c_felodipinePAA_liq_1um_3.000 crop750 
5.2b / 5.4a cjs_20150206_NPG_c_felodipinePVP_liq_2um_3.001 crop750 
5.2c / 5.4g cjs_20150221_SNL_c_felodipineHPMCAS_liq_1um_2.002 crop750 
5.2d / 5.4c cjs_20150122_NPG_c_felodipinePVAc_liq_2um_3.000 crop750 
5.2e cjs_20150505_SNL_c_felodipine_liq_1um_2.004 crop750 




5.4d cjs_20150217_SNL_c_felodipinePVPVA_liq_1um_2.000 crop750 
5.4e cjs_20150303_SNL_c_felodipinePVPandPVAc_liq_1um_2.000 crop750 
5.4f cjs_20150605_NPG_c_felodipinePVPVA10_2_liq_3um_1.000 crop750 
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